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The cannabinoid receptor 2 (CB2R) has been linked with the regulation of inﬂammation, and selective
receptor activation has been proposed as a target for the treatment of a range of inﬂammatory diseases
such as atherosclerosis and arthritis. In order to identify selective CB2R agonists with appropriate phys-
icochemical and ADME properties for future evaluation in vivo, we ﬁrst performed a ligand-based virtual
screen. Subsequent medicinal chemistry optimisation studies led to the identiﬁcation of a new class of
selective CB2R agonists. Several examples showed high levels of activity (EC50 < 200 nM) and binding
afﬁnity (Ki < 200 nM) for the CB2R, and no detectable activity at the CB1R. The most promising example,
DIAS2, also showed favourable in vitro metabolic stability and absorption properties along with a clean
selectivity proﬁle when evaluated against a panel of GPCRs and kinases.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The endocannabinoid system (ECS) is an endogenous signalling
pathway that has a regulatory role in pain perception, the immune
response, metabolism and mood. Among the key components of
the ECS are the cannabinoid receptors 1 and 2 (CB1R and CB2R).
While CB1R is predominantly expressed in the central nervous sys-
tem, CB2R is mainly expressed in peripheral tissues, particularly
immune cells,1,2 although studies over the last decade have shown
that CB2R is also expressed in the CNS in microglia3 and brainstem
neurons,4 and that it is upregulated in response to injury in dorsal
root ganglia5 and sensory neurons.6
CB2R belongs to the G-Protein Coupled Receptor (GPCR) super-
family and mediates the downstream effects of endogenous
secreted cannabinoid receptor ligands (endocannabinoids) such
as anandamide and 2-arachidonoylglycerol (2-AG).7 Activation of
the CB2R has been shown to lead to a number of downstream sig-
nalling events,8 the most widely studied of which involve inhibi-
tion of adenylyl cyclase and lowering of intracellular cyclic AMPlevels,9 and mitogen-activated protein kinase (MAPK) activation10
via coupling through Gai/o proteins.
CB2R has been proposed as a therapeutic target for the treat-
ment of pain and inﬂammatory conditions.11 The main compo-
nents of marijuana including the tetrahydrocannabinol D9-THC
(1, Fig. 1) and other phytocannabinoids12 have long been knownnnabinol
ed CB2R
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activation of the CB1R as well as the CB2R.8,13 However the clinical
use of these agents is limited, in the most part due to their psycho-
tropic side effects which are thought to arise from activation of the
CB1R.14,15 Thus, there have been extensive studies in recent years
to develop selective CB2R modulators, particularly for the manage-
ment of pain.11,16 Indirect strategies to modulate the cannabinoid
receptors through inhibition of endocannabinoid metabolism are
also being explored.17
A variety of strategies have been explored to develop alterna-
tive CB2R agonists including structure activity relationship (SAR)
analyses around the structure of D9-THC (1) leading to the discov-
ery of compounds such as CP 55,940 (2, Fig. 1)18 and the selective
CB2R agonist, HU-308 (5, Fig. 2).19 A homology model of the CB2R
has been published using the crystal structure of bovine rhodop-
sin,20 and this and more recent reﬁne models have been employed
in virtual screening strategies to identify new classes of CB2R
ligand.21,22 The most commonly employed strategies have been
ligand-based virtual screening23 and high-throughput screening
approaches,11 for example, in the recent discovery of 4 by Lilly
(Fig. 1).24
Several CB2R selective agonists show efﬁcacy in in vivo models
of acute and chronic pain, and these effects are blocked upon co-
treatment with CB2R antagonists such as SR14452825 and
AM630,26 or in CB2R knockout animals, supporting a CB2R-medi-
ated mechanism of action.11 Despite these promising preclinical
data, only a few candidates have entered clinical trials to date for
evaluation in the treatment of inﬂammatory pain, and none has
progressed beyond Phase 2. For instance GW-842166X (3,
Fig. 1)27 was recently evaluated in a Phase 2a trial for acute inﬂam-
matory pain following third molar extraction,28 but failed to dem-
onstrate sufﬁcient efﬁcacy and has been discontinued. In this case
the lack of efﬁcacy was attributed to insufﬁcient exposure and
CB2R occupancy.28
Moreover, there is emerging in vivo data to support the role of CB2R
as a therapeutic target in other disease indications including osteopo-
rosis,29 multiple sclerosis30 or in other diseases with an inﬂammatory
component31 such as allergic contact dermatitis,32 colitis33,34 and ath-
erosclerosis.35 A non-psychoactive cannabinoid derivative, ajulemic
acid, has also been reported to show anti-inﬂammatory effects.36
CB2R activation has been shown to induce monocyte chemotaxis,37
and reduce macrophage chemotaxis to a range of chemoattractants
including MCP-1, MIP-1a, RANTES and fMLP.35,38,39 Support for CB2R
being a physiologically relevant modulator of macrophage inﬂamma-
tion in vivo came from analysis of endocannabinoid levels in human
atherosclerotic lesions in carotid arteries and reduced MMP-2 secre-
tionbyhuman inﬂammatory cells treatedwith theCB2R-selective ago-
nist JWH-133.40 There is therefore still a real need for additional highly
selective CB2R agonists with improved pharmacokinetic and pharma-Figure 2. (A) Structure and properties of HU-308 (5); (B) 3-D representation of the lowes
(5) and DIAS1 (6) using Forge (Cresset);45 (D) structure and properties of DIAS1 (6) andcodynamic proﬁles to evaluate their clinical efﬁcacy as anti-inﬂamma-
tory agents. To datemost groups have focussed onCNSpenetrant CB2R
ligands, many of which have high lipophilicity.41
Despite the range of current CB2R agonists available in the
published literature, there still exists a scientiﬁc need for new
CB2R-selective tool compounds that are less lipophilic and periph-
erally restricted that can be used to speciﬁcally address the role of
CB2R in modulating macrophage chemotaxis and activation in pre-
clinical models of inﬂammation.34 We therefore sought to identify
a new family of highly selective CB2R agonists with improved
in vitro ADME properties to investigate their use as peripherally-
restricted anti-inﬂammatory agents in a range of in vivo models.
Herein we report our preliminary discovery efforts towards this
overarching goal.
2. Results and discussion
We opted to employ a virtual ligand-based screening strategy in
order to identify new chemical scaffolds which exhibited agonist
activity at the CB2R to provide a starting point for initial SAR anal-
ysis and optimisation. A set of reported CB2R agonists and their
respective afﬁnities for CB1R and CB2R were assessed when making
the ﬁnal selection for the template ligand for the virtual screen (see
Supplementary Table S1). HU-308 (5, Fig. 2A) was chosen as the
query molecule for the virtual screen due to its high potency and
degree of selectivity for CB2R over the CB1R (> 400 fold).
2.1. Ligand-based virtual screening
Using the Omega (OpenEye) package, 40 possible low energy
conformers of HU-308 (5) were established based on the mini-
mised energy conformations of the molecule (kcal/mol) (example
in Fig. 2B).42 Up to 100 conformers were also generated of every
molecule in our 25,000-member in-house library.43 Finally the 40
conformers of HU-308 (5) were screened against the virtual library
using the programme rapid overlay of chemical structures (ROCS,
OpenEye).44 The screen was performed under default parameters
using full optimisation mode. The compounds were ranked in
order according to their shape similarity compared to any of the
40 conformers of HU-308 (5). The top 100 compounds that pre-
sented most similarity in their overlay with HU-308 (5) were of
interest, these overlay results were conﬁrmed through the use of
an independent alignment program, Forge (Cresset) (Fig. 2C).45
The overall score was based on a combination of two calculated
parameters: the colour score46 and shape Tanimoto score47 com-
bined, provided the combo score47 by which the compounds were
ranked (see Supplementary Table S2). On the basis of this ranking
the top 94 available compounds were selected for screening for
CB2R activation.t energy conformer of HU-308 (5) using Omega (OpenEye);42 (C) overlay of HU-308
DIAS2 (7). aCalculated using the c logP algorithm in ChemBioDraw 14.0.
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The 94 compounds were screened using a commercially avail-
able complementation immunoassay measuring levels of b-galac-
tosidase (b-gal) labelled cAMP.48 The assay was performed using
CB2R-expressing Chinese Hamster Ovary (CHO) cells stimulated
with forskolin. In the absence of an agonist binding to the CB2R,
intracellular cAMP competes with labelled cAMP for binding to
the anti-cAMP antibody increasing levels of free b-gal labelled
cAMP in the cell. The addition of a CB2R agonist leads to inhibition
of adenylate cyclase activity by the Gai complex formed upon
receptor activation. This in turn leads to a lowering of the level
of intracellular cAMP, increased sequestration of labelled cAMP
by the anti-cAMP antibody and thus a decrease in the level of free
b-gal labelled cAMP.
From the compounds tested several CB2R activators were iden-
tiﬁed as having modest activity. Six different cores were present in
the top 16 hits. Interestingly the compound that ranked highest in
the virtual screen did not demonstrate the highest activity in the
in vitro assay. DIAS1 (6) was selected for further evaluation
(Fig. 2D) on the basis of its activity, relatively lowmolecular weight
(258 Da), and predicted lower lipophilicity compared to HU-308
(c logP HU-308, 6.9; c logP DIAS1, 4.2). This compound exhibited
good activity and in a dose dependent manner at the CB2R, 3 lM
(57.2%) and 1 lM (52.1%). The selected compound ranked 13th in
the virtual screen based on its combo score (see Supplementary
Table S2). An overlay of DIAS1 (6) with HU-308 (5) using Forge45
illustrates good alignment of the hydrophobic alkyl chains and
the aromatic core in both molecules (Fig. 2C).
Following the identiﬁcation of 6 as an active hit, our compound
library was further mined using the 3-mercapto triazinoindole core
of 6 to identify available molecules with the same substructure to
allow screening of close analogues, and an evaluation of prelimin-
ary SARs. This search identiﬁed a small number of additional com-
pounds with variations at C(3) and N(5) positions of the tricyclic
core. The compounds were screened in the cAMP assay (Fig. S1)
and one, DIAS2 (7) exhibited improved activity (EC50 = 120 nM),
in comparison to DIAS1 (6) (EC50 = 296 nM) with a reduced c logP
value (3.8). Interestingly DIAS2 was not amongst the top 16 ranked
compounds in the virtual screen, nor did it appear in the top 400
compounds based on their combo score. This discrepancy may
reﬂect the accuracy of the algorithms used but may also just reﬂect
a limitation in this ligand-based screening method: for instance
hits are ranked on the basis of similarity to a probe ligand (in this
case HU-308) and not on the basis of predicted best ﬁt with the
CB2R.
2.3. Hit validation of DIAS1 (6) and DIAS2 (7)
Veriﬁcation of the activity of DIAS1 (6) and DIAS2 (7) was car-
ried out via the re-synthesis of an authentic sample. Compounds
6 and 7were synthesised via a cyclisation of isatin 8with thiosem-
icarbazide to yield the tricycle 9,49 followed by alkylation or benzy-Scheme 1. Reagents and conditions: (i) thiosemicarbazide, K2CO3, H2O, reﬂux,
16 h; (ii) butyl iodide or 2-cyanobenzyl bromide, NEt3, MeOH, rt, 16 h.lation of 9 to yield 6 and 7 in an overall yield of 76% and 79%,
respectively (Scheme 1).50,51
The resynthesised samples of DIAS1 (6) and DIAS2 (7) gave EC50
values of 296 and 112 nM, respectively, in the cAMP assay. Having
conﬁrmed the functional activity of DIAS1 (6) and DIAS2 (7) as
CB2R agonists, attention next turned to exploring preliminary
structure–activity-relationships within this series in order to opti-
mize activity.
2.4. DIAS2 optimisation: variation at C(3)
The ﬁrst region of the tricyclic moiety to be explored was the
C(3) benzyl thiol moiety. A synthetic route enabling a library to
be efﬁciently enumerated was optimised from the previous syn-
thesis of 7 via intermediate 9. This common intermediate was used
to prepare a series of compounds representing S-alkyl, S-aryl and
S-benzyl substituted derivatives. Intermediate 9 allowed efﬁcient
substitution of a range of alkyl and arylmethyl halides in the pres-
ence of Et3N to yield the S-substituted compounds 10–11 and
12–24, which were isolated in 50% to quantitative yield (Scheme 2).
The array of C(3)-substituted triazinoindoles were evaluated for
activity at the CB2R using the CHO cell assay described above. The
preliminary SAR assessment had demonstrated that the presence
of linear thioalkyl groups C(3) larger than n-butyl led to a reduction
in activity at the CB2R (Table S2), and it was therefore of interest to
determine whether a small thiomethyl (10) substituent, or more
bulky b-branched thiomethylcyclohexyl (11) would show activity
at the CB2R. Compound 11 was also of particular interest as a fully
saturated counterpart for comparison with the C(3)-thiobenzyl
substituted analogues. Intermediate 9 was also tested and showed
no detectable agonist activity at the CB2R, nor did the C(3)-thio-
methyl- or C(3)-thiomethylcyclohexyl-substituted derivatives 10
and 11 (EC50 > 3000 nM, Table 1).
Having established a relatively restricted tolerance for varia-
tions in C(3)-thioalkyl substituents, attention turned to exploring
systematic variations of C(3)-thiobenzyl substituents. To this end
a selection of compounds with varying aryl substituents and regio-
chemistry were prepared and assayed (Table 1). Interestingly,
removal of the cyano group (C(3)-thiobenzyl, 12) led to a reduction
in activity at the CB2R (EC50 = 10,000 nM, Table 1). Regiochemistry
was also found to inﬂuence activity, with 3-cyano substituted
derivative 13 showing markedly reduced activity at the CB2R com-
pared to its 2-cyano substituted counterpart DIAS2 7 (13:
EC50 = 6450 nM; 7 EC50 = 112 nM, Table 1). Introduction of ﬂuoro
or chloro substituents at any site on the aryl ring showed no
detectable activity (14–19; EC50 > 3000 nM, Table 1). In contrast,
the 2-nitro substituted derivative 20 showed good levels of activity
at the CB2R (EC50 = 33 nM, Table 1); regiochemistry was again
found to inﬂuence activity, with the 4-nitro substituted counter-
part (21) showing reduced activity at the CB2R (EC50 = 617 nM,
Table 1).
These initial SAR observations suggested that there was a pref-
erence for electron withdrawing groups incorporating a hydrogen
bond acceptor in the ortho site of the C(3)-thiobenzyl group. Previ-
ous studies have sought to rank and quantify hydrogen bond
acceptor ability of various functional groups,52 and it was noted
that examples incorporating a good hydrogen bond acceptor in
the ortho site of the S-benzyl group such as nitro (20) and cyano
(7) showed the highest levels of activity compared to poorer
hydrogen bond acceptors such as halogens (14 and 17). Three fur-
ther examples were therefore synthesized in order to further probe
any relationship between electron withdrawing ability or hydro-
gen bond acceptor ability and activity: o-triﬂuoromethoxy (23),
o-ethoxycarbonyl (24) and o-carboxylic acid (25, prepared through
saponiﬁcation of the corresponding ester 24). Triﬂuoromethoxy
substituted derivative 23 showed no detectable activity at the
Table 1
Variation of sulﬁde substituent and effects on CBR activity and afﬁnity. EC50 determined using CHO cells expressing hCB2R/hCB1R. Ki determined using radioligand displacement
assay using either [3H]WIN-55212-2 (CB2R) or [3H]CP 55,940 (CB1R). All assays were performed in duplicate
Entry ID R1 R2 Yield from 9 (%) EC50 (CB2R) (nM) EC50 (CB1R) (nM) Ki (CB2R) (nM) Ki (CB1R) (nM)
1 10 Me — 95 >3000 N.D. N.D. N.D.
2 6 (DIAS1) n-Bu — 80 296 N.D. N.D. N.D.
3 11 c-Hexylmethyl — 67 >3000 N.D. N.D. N.D.
4 12 — Ph 75 10,000 >30,000 N.D. N.D.
5 7 (DIAS2) — 2-CN–C6H4– Quant. 112 >30,000 355 >60,000
6 13 — 3-CN–C6H4– 58 6450 >30,000 N.D. N.D.
7 14 — 2-F–C6H4– 57 >3000 N.D. N.D. N.D.
8 15 — 4-F–C6H4– 82 >3000 N.D. N.D. N.D.
9 16 — 2,6-F2–C6H3– 54 >3000 N.D. N.D. N.D.
10 17 — 2-Cl–C6H4– 79 >3000 N.D. N.D. N.D.
11 18 — 3-Cl–C6H4– 73 >3000 N.D. N.D. N.D.
12 19 — 4-Cl–C6H4– 59 >3000 N.D. N.D. N.D.
13 20 — 2-NO2–C6H4– 98 33 >30,000 155 >60,000
14 21 — 4-NO2–C6H4– 62 617 N.D. N.D. N.D.
15 22 — 2-CF3–C6H4– 74 >3000 N.D. N.D. N.D.
16 23 — 2-OCF3–C6H4– 50 >3000 N.D. N.D. N.D.
17 24 2-CO2Et–C6H4– 83 >3000 N.D. N.D. N.D.
18 25 — 2-CO2H–C6H4– 99 2185 N.D. N.D. N.D.
N.D. = not determined.
Scheme 2. Reagents and conditions: (i) alkyl halide, Et3N, MeOH, rt, 16 h; (ii) benzyl halide, Et3N, MeOH, rt, 16 h; (iv) NaOH (aq), rt, 16 h.
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group cannot be accommodated at this site. Interestingly, both
ester 24 and carboxylic acid 25 displayed little or no detectable
activity at the CB2R (24: EC50 > 3000 nM; 25 EC50 = 2185, Table 1)
despite both groups being good hydrogen bond acceptors.
The effect of varying the linker between C(3) and the aryl group
was also investigated. DIAS2 (7) was oxidised chemoselectively to
the corresponding sulfoxide 26 in 95% yield using a mixture of tri-
ﬂuoroacetic acid and peroxytriﬂuoroacetic acid (Scheme 3). Com-
pound 26 was also considered as a potential metabolite of DIAS2
so it was of further interest to determine the effect of S-oxidation
on bioactivity. However, S-oxidation led to a signiﬁcant reduction
of activity at the CB2R (26: EC50 = 3550 nM, Scheme 3).
Representative compounds showing activity at the CB2R were
also assessed for activity at the CB1R again using a complementa-
tion immunoassay measuring levels of b-galactosidase (b-gal)
labelled cAMP, analogous to the assay used to measure CB2R activ-
ity.48 The assay was performed using CB1R-expressing CHO cells
stimulated with forskolin and D9-THC, a non-speciﬁc CB1R agonist,
was used as a positive control (data not shown). DIAS2 (7) and ana-
logues 12, 13 and 20 were all evaluated for activity at the CB1R but
none showed any detectable agonist activity up to the highest con-
centrations tested (EC50 > 30,000 nM, Table 1).
In addition to measuring the functional activity of these com-
pounds at the CB1R and CB2R, the binding afﬁnity of representativeScheme 3. Reagents and conditions: (i) CF3CO3H, CF3CO2H, rt, 16 h.examples at both receptors was determined, in order to measure Ki
values. Two representative compounds, 2-nitro- and 2-cyano-
substituted S-benzyl derivatives (20 and 7) were thus assessed
for CB1R and CB2R afﬁnity using a radioligand displacement assay.
Compound binding was measured by displacement of [3H]-CP
55,940 or [3H]-WIN55212-2 in CHO cells expressing the human
CB1R or CB2R, respectively.53
These studies conﬁrmed the binding of 20 and 7 to the CB2R (7:
Ki = 355 nM; 20: Ki = 155 nM, Table 1). No binding was detected at
the CB1R for either compound (Ki > 60,000 nM, Table 1) providing
further support for the development of this series of compounds
as selective CB2R agonists.
2.5. DIAS2 optimisation: variation at C(6)–C(9)
Having established preliminary structure–activity-relationships
through variation at C(3), attention next turned to exploring the
effect of introducing a substituent at C(6)–C(9) of the tricyclic core.
In an initial effort to establish which position could tolerate further
substitution, a bromo substituent was introduced at each of the
four available sites. Following the same synthetic procedure devel-
oped for the preparation of DIAS2 (7), bromoisatins 27–30 were
ﬁrst treated with thiosemicarbazide to afford the corresponding
tricyclic species 31–34 in 34–97% yield (Scheme 4). Intermediates
31–34 were subsequently treated with 2-cyanobenzyl bromide to
give the bromo-substituted tricyclic derivatives 35–38 in 64–92%
yield. 9-Bromo substituted tricycle 39 was also prepared in 66%
yield by treating 35 with 2-nitrobenzyl bromide (Scheme 4).
The bromo-substituted tricycles 36–40 were assessed for CB2R
activity using the CHO cell assay. Introducing a bromo substituent
at C(6) (35), C(7) (36) or C(8) (37) was observed to lead to a loss of
activity at the CB2R in all cases (EC50 > 3000 nM, Table 2). Con-
versely, 38 and 39 both of which incorporated a bromo substituent
at C(9) maintained good levels of activity at the CB2R (EC50 = 39
and 37 nM, respectively, Table 2). The 9-bromo derivative 38 was
Table 2
Variation of the substitution pattern around the triazinoindole core and effects on
CBR activity and afﬁnity. EC50 determined using CHO cells expressing hCB2R/hCB1R. Ki
determined using radioligand displacement assay using either [3H]WIN-55212-2
(CB2R) or [3H]CP 55,940 (CB1R). All assays were performed in duplicate
Entry ID EC50 (CB2R)
(nM)
EC50 (CB1R)
(nM)
Ki (CB2R)
(nM)
Ki (CB1R)
(nM)
1 7 112 >30,000 355 >60,000
2 35 >3000 N.D. N.D. N.D.
3 36 >3000 N.D. N.D. N.D.
4 37 >3000 N.D. N.D. N.D.
5 38 39 20,000 22.5 3200
6 39 37 N.D. N.D. N.D.
Scheme 4. Reagents and conditions: (i) thiosemicarbazide, K2CO3, H2O, rt, 16 h; (ii)
benzyl halide, Et3N, MeOH, rt, 16 h.
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with DIAS2 (7). Compound 38 showed high binding afﬁnity at
the CB2R and weak to moderate afﬁnity at the CB1R (Ki = 22.5
and 3200 nM, respectively, Table 2). In accordance with the afﬁnity
studies, 38 also showed very weak agonist activity when evaluated
in CB1R-expressing CHO cells (EC50  20,000 nM, Table 2).
Having established that introducing a bromo substituent at C(9)
was tolerated, we sought to further explore the effect of varying
the C(9) group on activity and afﬁnity at the CB2R. It was envisaged
that a selection of groups could be introduced at this position via a
Suzuki cross-coupling reaction using 4-bromoisatin 30 as starting
material.54 4-(30-Thienyl)isatin 41, 4-(20-methylphenyl)isatin 42
and 4-(40-methylphenyl)isatin 43 were all prepared in moderate
to good yield via a Pd(PPh3)4Cl2-mediated cross-coupling using
4-bromoisatin and the corresponding potassium triﬂuoroborate
salts.55 The intermediates 41–43 were next treated stepwise with
thiosemicarbazide then 2-cyanobenzyl bromide to afford the
C(9)-substituted derivatives 50–52 in 17–50% yield over the two
steps (Scheme 5).
Treatment of 4-bromoisatin 30 with either cyclopropyl boronic
acid or potassium cyclopropyl triﬂuoroborate under a range of con-Scheme 5. Reagents and conditions: (i) NaH, 4-methoxybenzyl chloride, DMF, 0 C,
30 min then 40 C, 3 h; (ii) Potassium aryl triﬂuoroborate, K3PO4, Pd(PPh3)2Cl2, THF/
H2O (3:1), 130 C, MW, 4 h; (iii) Potassium cyclopropyl triﬂuoroborate, K3PO4,
Pd(dppf)2Cl2, THF/H2O (3:1), 130 C, MW, 4 h; (iv) thiosemicarbazide, K2CO3, H2O,
reﬂux, 16 h; (v) 2-cyano benzyl bromide, Et3N, MeOH, rt, 16 h; (vi) CF3CO2H, 90 C,
16 h.ditions gave no conversion to the desired 4-cyclopropylisatin
product. To circumvent this problem, isatin was ﬁrst treated
with 4-methoxybenzyl chloride and sodium hydride to give the
corresponding N-PMB protected isatin 40. Treatment of 40 with
potassium cyclopropyl triﬂuoroborate and Pd(dppf)2Cl2 afforded
44 in 96% yield. Cyclisation, S-benzylation and deprotection using
triﬂuoroacetic acid gave 9-cyclopropyl substituted derivative 53
in 46% yield over the three steps (Scheme 5).
The array of C(9)-substituted compounds were evaluated for
CB2R activity using the CHO cell assay. While 9-cyclopropyl-substi-
tuted derivative 53 showed good levels of activity at the CB2R
(EC50 = 231 nM, Table 3), introducing a bulkier 2-thienyl substitu-
ent at C(9) led to a reduction in activity at the CB2R (52:
EC50 = 1760 nM, Table 3). Of the two C(9)-aryl substituted deriva-
tives tested (50 and 51) both showed markedly reduced activity
at the CB2R (50: EC50 = 4300 nM; 51: EC50 > 3000 nM, Table 3).
In an effort to rationalise the steep SAR observed upon variation
at C(9), lowest energy conformers were calculated for representa-
tive examples using the Maestro modelling package (Schrodinger):
51 (p-methylphenyl substituted), 52 (3-thienyl substituted) and 53
(cyclopropyl substituted) (Fig. 3). The results suggest that 51 and
52 both preferentially adopt a non-planar conformation about
the exocyclic C(9)AC bond, consistent with the conformational
preferences of ortho-substituted biaryls. A possible explanation
for the reduced activity of 52 compared to 7 and 38, and the lack
of detectable activity of 51, could be that this non-planar confor-
mation cannot be accommodated upon binding to the CB2R.
Compound 53 is predicted to have a number of low energy con-
formers, one of which is depicted in Figure 3. The two carbons at
the base of the cyclopropyl ring can either be oriented above or
below the plane of the tricycle, and thus a possible explanation
for the moderate CB2R agonist activity of 53 is that one of these
conformers can be accommodated upon binding to the receptor.
2.6. DIAS2 optimisation: variation at N(5)
Having investigated the effects of varying substituents at C(3)
and C(6)–C(9) attention next turned to exploring the effect of
introducing a substituent at N(5). It was envisaged that a range
of N-substituted derivatives could be readily prepared from the
corresponding S-substituted tricycles. Several conditions were tri-
alled, but the optimal route was found to be treatment of triazen-
oindoles 7, 14 and 20 with NaH (60% dispersion in mineral oil) in
DMF followed by the requisite electrophile giving a range of N-
alkyl, N-benzyl, N-sulfonyl, N-oxycarbonyl and N-acyl substituted
analogues in 19–96% yield (Scheme 6). Three N-acyl substituted
examples could not be accessed using this method, and were
therefore prepared using alternative conditions by treating the
triazenoindole with DMAP and the requisite acyl chloride: this
afforded 73 from 20 in 73% yield, and 78–79 from 7 in 55% and
56% yield, respectively (Scheme 6).
The array of N(5)-substituted analogues were evaluated for
activity at the CB2R in the CHO cell assay. A much broader range
of substituents appeared to be tolerated, with most of the deriva-
tives prepared and tested showing some agonist activity at the
CB2R (Table 4). Of the N-alkyl substituted variants, N-methyl
derivative 54 showed no detectable activity at the CB2R
(EC50 > 3000 nM, Table 4), consistent with the preliminary SAR
assessment (Table S2 and Fig. S1). In contrast larger linear N-alkyl
groups, N-ethyl 55 and N-(n-butyl) 56, and b-branched N-alkyl
groups, N-cyclopropylmethyl 57 and N-cyclohexylmethyl 58, were
all tolerated and showed similar activities at the CB2R (55:
EC50 = 674 nM; 56: EC50 = 106 nM; 57: EC50 = 144 nM; 58:
EC50 = 270 nM, Table 4).
N-Benzyl substituted derivatives 59 and 61 also showed similar
levels of activity at the CB2R compared to their unsubstituted
Table 3
Variation of substituents at C9 of triazinoindole core and effects on CB2R activity and afﬁnity. EC50 determined using CHO cells expressing hCB2R. All assays were performed in
duplicate
Entry ID R Yield (step (i) or (ii), %) Yield (steps (iii)–(iv), %) EC50 (CB2R) (nM)
1 7 H — — 112
2 50 o-MeC6H4– 42 55 4300
3 51 p-MeC6H4– 68 17 >3000
4 52 3-Thienyl 59 50 1760
5 53 Cyclopropyl 43 44 231
Figure 3. 3-D representations of calculated lowest energy conformers of 51, 52, and
53. Calculations were performed using Maestro (Schrodinger).
Scheme 6. Reagents and conditions: (i) electrophile, NaH (60% dispersion in
mineral oil), DMF or THF, 0 C–rt, 16 h; or DMAP, CH2Cl2, rt, 16 h.
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Table 4). Interestingly, N-benzyl S-(2-ﬂuorobenzyl) derivative 60Table 4
Variation of substituents at N5 of triazolyl-indole core and effects on CBR activity and afﬁ
radioligand displacement assay using either [3H]WIN-55212-2 (CB2R) or [3H]CP 55,940 (C
Entry ID R1 R3 Yield (%)
1 7 2-CN–C6H4CH2– H N/A
2 14 2-F–C6H4CH2– H N/A
3 20 2-NO2–C6H4CH2– H N/A
4 54 2-CN–C6H4CH2– Me 69
5 55 2-CN–C6H4CH2– Et 78
6 56 2-CN–C6H4CH2– n-Bu 68
7 57 2-CN–C6H4CH2– Cyclopropylmethyl 52
8 58 2-CN–C6H4CH2– Cyclohexylmethyl 19
9 59 2-CN–C6H4CH2– Benzyl 80
10 60 2-F–C6H4CH2– Benzyl 40
11 61 2-CN–C6H4CH2– 2-NO2–C6H4–CH2– 96
12 62 2-CN–C6H4CH2– PhSO2– 84
13 63 2-CN–C6H4CH2– 4-Me–C6H4SO2– 92
14 64 2-CN–C6H4CH2– 2-NO2–C6H4SO2– 83
15 65 2-CN–C6H4CH2– BnOCO– 96
16 66 2-CN–C6H4CH2– MeCO– 77
17 67 2-CN–C6H4CH2– Cyclopropylcarbonyl 76
18 68 2-CN–C6H4CH2– Cyclopentylcarbonyl 42
19 69 2-CN–C6H4CH2– Cyclohexylcarbonyl 71
20 70 2-CN-C6H4CH2- MeCO2CH2CH2CO– 81
21 71 2-CN–C6H4CH2– MeCO2CH2CH2CH2CO– 81
22 72 2-CN–C6H4CH2– PhCO– 72
23 73 2-NO2–C6H4CH2– PhCO– 73
24 74 2-CN–C6H4CH2– 4-F–C6H4CO– 67
25 75 2-CN–C6H4CH2– 3-CF3–C6H4CO– 58
26 76 2-CN–C6H4CH2– 2-CF3–4-F–C6H3CO– 42
27 77 2-CN–C6H4CH2– 4-(CF3O)–C6H4CO– 67
28 78 2-CN–C6H4CH2– 4-NMe2–C6H4CO– 55
29 79 2-CN–C6H4CH2– 3,4-(MeO)2–C6H3CO– 56
30 80 2-CN–C6H4CH2– 2-Furfurylcarbonyl 78
31 81 2-CN–C6H4CH2– 5-Isoxazolylcarbonyl 85
32 82 2-CN–C6H4CH2– 1-Morpholinocarbonyl 72
N.D. = not determined.showed moderate activity at the CB2R in contrast to its N(5)-
unsubstituted counterpart 14, which showed no activity up to
the highest concentrations tested (60: EC50 = 850 nM, Table 4). In
order to conﬁrm the activity of the N-substituted derivatives and
determine Ki values, N-benzyl substituted derivatives 59 and 60
and N-(2-nitro)benzyl 61were selected as representative examples
for CB2R and CB1R afﬁnity studies. All were found to have moderate
to high binding afﬁnity for the CB2R (59: Ki = 11 nM; 60: Ki = 215 nM;
61: Ki = 290 nM; Table 4), and intriguingly both 59 and 60 also
showed similar levels of binding afﬁnity for the CB1R (59: Ki = 61 nM;
60: Ki = 275 nM; Table 4). These binding afﬁnity measurements
were supported by subsequent functional activity studies at the
CB1R: 59 showed moderate agonist activity in CB1R-expressing
CHO cells (EC50 = 1553 nM, Table 4). These results were in com-
plete contrast to the analogues with no substituent at N(5) which
showed no afﬁnity or activity at the CB1R up to the highest concen-
trations tested. Furthermore N-(2-nitro)benzyl 61 showed no afﬁn-
ity or activity at the CB1R up to the highest concentrations tested
(Ki, EC50 > 60,000 nM, Table 4), providing additional useful insights
into the requirements for CB1R/CB2R selectivity in this series.nity. EC50 determined using CHO cells expressing hCB2R/hCB1R. Ki determined using
B1R). All assays were performed in duplicate
EC50 (CB2R) (nM) EC50 (CB1R) (nM) Ki (CB2R) (nM) Ki (CB1R) (nM)
112 >30,000 355 >60,000
>3000 N.D. N.D. N.D.
33 >30,000 155 >60,000
>3000 N.D. N.D. N.D.
674 N.D. N.D. N.D.
106 N.D. N.D. N.D.
144 N.D. N.D. N.D.
270 N.D. N.D. N.D.
214 1553 11 61
850 N.D. 215 275
53 >30,000 290 >60,000
76 N.D. N.D. N.D.
>3000 N.D. N.D. N.D.
>3000 N.D. N.D. N.D.
>3000 N.D. N.D. N.D.
>3000 N.D. N.D. N.D.
181 N.D. N.D. N.D.
49 N.D. 320 >60,000
32 N.D. 30 >60,000
48 N.D. 360 >60,000
42 N.D. N.D. N.D.
113 N.D. 300 >10,000
75 N.D. 235 >60,000
57 N.D. N.D. N.D.
27 N.D. N.D. N.D.
>3000 N.D. N.D. N.D.
73 N.D. 380 >60,000
>3000 N.D. N.D. N.D.
160 N.D. N.D. N.D.
46 N.D. 490 >10,000
19 N.D. 450 >60,000
92 N.D. N.D. N.D.
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investigated. N-Phenylsulfonyl derivative 62 showed comparable
levels of activity at the CB2R to DIAS2 7 (EC50 = 76 nM, Table 4).
However, introducing functional groups to the N-phenylsulfonyl
substituent (exempliﬁed by N-4-methylphenyl sulfonyl 63 and N-
2-nitrophenyl sulfonyl 64) led to loss of detectable activity up to
the highest concentration tested (EC50 > 3000 nM, Table 4). The
reasons for this unexpectedly steep SAR are unclear at this time.
N-Benzyloxycarbonyl derivative 65 showed no detectable activity
at the CB2R (EC50 > 3000 nM; Table 4). Of more concern was the
fact that the N-sulfonyl and N-oxycarbonyl derivatives were also
found to show limiting solubility, even in the vehicle (DMSO),
and therefore neither series were pursued further.
A series of aliphatic N-acyl substituted derivatives were next
examined. While N-acetyl analogue 66 showed no detectable activ-
ity at the CB2R, all other aliphatic N-acyl substituted analogues
tested showed good levels of activity: N-cyclopropylcarbonyl 67,
N-cyclopentylcarbonyl 68 and N-cyclohexylcarbonyl 69 all showed
comparable activity with DIAS2 7 (67: EC50 = 181 nM; 68:
EC50 = 49 nM; 69: EC50 = 32 nM, Table 4). These observations were
consistent with the trend in activity for the N-alkyl substituted ser-
ies—small N-substituents show no or reduced activity at the CB2R.
It was also of interest to determine whether polar groups could be
accommodated within the N(5) substituent as it was envisaged
these would aid with improving other important parameters such
as solubility, lipophilicity and potentially metabolism. Thus,
homologous esters 70 and 71were prepared and evaluated for ago-
nist activity at the CB2R: encouragingly both showed good levels of
activity (70: EC50 = 48 nM; 71: EC50 = 42 nM, Table 4). N-Cyclopen-
tyl 68, N-cyclohexyl 69 and ester 70 were also selected as repre-
sentative examples for CB2R/CB1R binding afﬁnity studies. All
showed high afﬁnity at the CB2R, consistent with the activity
observed in CB2R-expressing CHO cells (68: Ki = 320 nM; 69:
Ki = 30 nM; 70: Ki = 360 nM, Table 4), but no detectable activity
up to the highest concentrations tested at the CB1R (Ki > 60,000 -
nM), Table 4).
The introduction of an N-benzoyl group 72 led to comparable
levels of activity at the CB2R (EC50 = 113 nM, Table 4) to DIAS2 7
and its N-benzyl substituted counterpart 59. Similarly, N-benzoyl
derivative 73 also showed comparable activity at the CB2R
(EC50 = 75 nM, Table 4) to its N(5)-unsubstituted counterpart 20.
Both N-benzoyl substituted derivatives 72 and 73 were selected
for CB2R and CB1R afﬁnity studies: both showed good afﬁnity for
the CB2R (72: Ki = 300 nM; 73: Ki = 235 nM; Table 4) and no detect-
able binding at the CB1R (72: Ki > 10,000 nM; 73: Ki > 60,000 nM,
Table 4). Interestingly the lack of CB1R binding observed for N-ben-
zoyl substituted species 72was in contrast to the data obtained for
its N-benzyl substituted counterpart 59 (Ki = 61 nM, Table 4). This
suggests that the presence of the carbonyl functionality is not tol-
erated by the CB1R, possibly as it introduces a polar interaction or
preferentially adopts a conformation that cannot be accommo-
dated at the receptor.
Having established that the introduction of a benzoyl substitu-
ent at N(5) retained activity and afﬁnity at the CB2R, and selectivity
over the CB1R, a number of substituted analogues were next
explored. All para- andmeta-substituted analogues showed similar
levels of activity at the CB2R compared to their N-benzoyl substi-
tuted counterpart 72 (74, 4-ﬂuoro: EC50 = 57 nM; 75, m-triﬂuoro-
methyl: EC50 = 27 nM; 77, p-triﬂuoromethoxy: EC50 = 73 nM; 79,
m-, p-dimethoxy: EC50 = 160 nM; Table 4), except for 4-dimethyl-
amino substituted derivative 78 which showed no detectable
activity at the CB2R (EC50 > 3000 nM, Table 4). It was noted that
78 was extremely poorly soluble under the assay conditions, and
this may have led to the lack of observable activity. Introducing a
triﬂuoromethyl group in the ortho site up to the highest concentra-
tions tested (EC50 > 3000 nM, Table 4). Both of the examples inves-tigated had comparatively bulky ortho substituents (A-values:
CF3 = 2.1 kcal/mol; NO2 = 1.13 kcal/mol56) and it is therefore possi-
ble that the reduced conformational freedom and the preferred
conformations cannot be accommodated at the CB2R.
A selection of heterocyclic substituents were next investigated
as these were anticipated to confer more favourable physicochem-
ical properties. N-(2-Furfuryl)carbonyl (80), N-(5-isoxazolyl)car-
bonyl (81) and N-(1-morpholino)carbonyl (82) derivatives were
prepared and, as anticipated, all showed good activity at the
CB2R (80: EC50 = 46 nM; 81: EC50 = 19 nM; 82: EC50 = 92 nM;
Table 4). In subsequent afﬁnity studies, representative examples
80 and 81 also showed good afﬁnity for the CB2R (80: Ki = 490 nM;
81: Ki = 450 nM, Table 4), and no afﬁnity at the CB1R (80:
Ki > 10,000 nM; 81: Ki > 60,000 nM, Table 4).
2.7. Evaluation of physicochemical properties and metabolic
stability of DIAS2 and analogues
An analysis of commonly employed synthetic and semi-syn-
thetic cannabinoid receptor modulators revealed that the majority
are highly lipophilic, with high c logP and logD values (HU-308:
c logP = 8.0, Table S1). This is perhaps not surprising given the pref-
erence of cannabinoid receptors for lipophilic endogenous ligands.
Moreover, the majority of cannabinoid receptor modulators to date
have been developed and investigated for neuroinﬂammation and
neuropathic pain indications and therefore require good distribu-
tion into the brain and CNS, a property often associated with higher
than average log D values.57,58 To investigate the effects of CB2R
agonists in peripheral pain and inﬂammation it was of interest to
generate compounds with reduced lipophilicity in the hope that
this would translate into reduced accumulation in the CNS and
an improved pharmacokinetic proﬁle. Given the relative expres-
sion patterns of CB2R (predominantly peripheral tissue)1,2 and
CB1R (predominantly CNS)3,4 it was also antipated that aiming
for a peripherally restricted molecule would lead to improved
in vivo efﬁcacy and reduced side-effects.
Values for c logP were therefore calculated for representative
active compounds to allow comparisons to be made (Table 5). Rel-
ative values for lipophilic ligand efﬁciency (LLE) were also calcu-
lated based on the corresponding EC50 values for each
compound. LLE has been shown to be a useful parameter in medic-
inal chemistry—optimal values for LLE have been shown in many
studies to correlate with higher chances of success in the clinic.59
Moreover, a comparison of LLE within a series can give a good indi-
cation whether increasing activity may be directly related to
increasing lipophilicity—that is, it is likely to be a function of the
free energy of solvation and not an increase in the free energy of
binding to the receptor.60 While the value for c logP for DIAS1 (6)
was determined to be 4.2, c logP for DIAS2 (7) was determined to
be 3.2, with a correspondingly lower value for LLE, and was there-
fore deemed to be a promising candidate for optimisation and
development.59c,61 The c logP value for 20 was similar to DIAS2 7
(3.9), giving a proportionally higher value for LLE (3.7) due to its
modestly increased activity. Unsurprisingly the c logP value for 9-
bromo substituted derivative 38was higher than DIAS2 (4.6), lead-
ing to a correspondingly lower value for LLE (2.8).
It was of particular interest to compare the values for c logP and
LLE for a selection of the N-substituted variants. It was observed
that a range of groups were tolerated at this site, and it was there-
fore anticipated that those examples incorporating polar functional
groups would give more favourable values for c logP and thus pro-
portionally higher values for LLE. As anticipated, N-alkyl- and N-
benzyl substituted derivatives 56–59 all had higher c logP values
(4.6–6.2), and correspondingly much lower values for LLE (0.3–
2.3). Similarly, N-phenylsulfonyl (62), N-cyclopropylcarbonyl (67)
and N-benzoyl (72) had similar or higher values for c logP to DIAS2
Figure 4. pEC50 and c logP correlation of triazinoindole series.
Figure 5. DIAS 2 (7) and its key pharmacological, physicochemical and in vitro
ADME properties. aCalculated using ChemDraw v13.0. bDetermined using MDCK-
MDR1 cells. c<30% activity when tested at 10 lM against a panel of 12 GPCRs (see
Supporting information). d<30% activity when tested at 10 lM against a panel of 96
kinases (see Tables S3 and S4).
Table 5
Variation of substituents at N(5) of triazinoindole core and effects on CB2R binding activity and afﬁnity, solubility and mouse liver microsome metabolic stability
Entry ID R1 R2 R3 EC50 (CB2R) (nM) c logPa LLE Solubilityb (lM) MLM stability t1/2 (min)
1 6 n-Bu H H 296 4.2 2.3 2.0 N.D.
2 7 2-CN–C2H4CH2– H H 112 3.8 3.2 3.75 46
3 20 2-NO2–C6H4CH2– H H 33 3.9 3.7 N.D. 43
4 38 2-CN–C2H4CH2– Br H 39 4.6 2.8 N.D. 5
5 56 2-CN–C2H4CH2– H n-Bu 106 5.2 1.5 N.D. <5
6 57 2-CN–C2H4CH2– H Cyclopropylmethyl 144 4.6 2.3 N.D. <5
7 58 2-CN–C2H4CH2– H Cyclohexylmethyl 270 6.2 0.3 N.D. <5
8 59 2-CN–C2H4CH2– H Benzyl 214 5.1 1.6 N.D. <5
9 62 2-CN–C2H4CH2– H PhSO2– 76 5.1 2.1 N.D. <5
10 67 2-CN–C2H4CH2– H Cyclopropylcarbonyl 181 3.8 3.0 N.D. <5
11 70 2-CN–C2H4CH2– H MeCO2CH2CH2CO– 48 3.3 4.0 3.75 N.D.
13 71 2-CN–C2H4CH2– H MeCO2CH2CH2CH2CO– 42 3.7 3.7 3.75 N.D.
14 72 2-CN–C2H4CH2– H PhCO– 113 4.6 2.4 2.0 —*
15 81 2-CN–C2H4CH2– H 5-Isoxylcarbonyl 19 2.6 5.2 6.5 N.D.
16 82 2-CN–C2H4CH2– H 1-Morpholinocarbonyl 92 3.1 3.9 10.5 N.D.
N.D. = not determined.
a Calculated using the c logP algorithm in ChemBioDraw 14.0.
b The value determined is the mid-point between the upper and lower solubility limits.
* Not observable even at the earliest time point, suggesting stability is very low and t1/2 was not calculable.
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67 = 3.0; 72 = 2.4). Conversely, all those derivatives incorporating
a polar group within the N(5) substituent had lower c logP values
and higher LLE values than DIAS2 (esters 70 and 71: c logP = 3.3
and 3.7, LLE = 4.0 and 3.7 respectively; 1-morpholinocarbonyl 82:
c logP = 3.1, LLE = 3.9). Of particular interest was N-(5-isoxazol-
yl)carbonyl substituted derivative 81, which had a c logP value of
2.6 and, due to its high activity at the CB2R, a high value for LLE
(5.2).
To further investigate any relationship between activity (in this
case pEC50) and c logPwithin this hit series, a plot correlating these
two parameters for each active compound was constructed (Fig. 4).
Supporting the analyses in Table 5, the plot showed no correlation
between c logP and activity (R2 < 0.2).
Besides c logP and LLE it was of real interest to optimise physi-
cochemical properties within the series, particularly aqueous solu-
bility. The majority of cannabinoid ligands described in the
literature are relatively poorly soluble in aqueous solution, pre-
sumably as a consequence of their high lipophilicity, a property
that limits their application as chemical tools. It was anticipated
that given that polar groups could be accommodated within the
N(5) substituent, aqueous solubility could also be tuned by varying
this substituent. Thus, the kinetic solubility of a selection of active
variants was measured at 37 C, pH 7.0 (Fig. 5).62
DIAS1 (6) showed low aqueous kinetic solubility (2.0 lM),
while DIAS2 (7) showed a slight improvement (3.75 lM, Table 5).
A selection of derivatives incorporating N-acyl and/or polar groups
within the N(5) substituent were next evaluated. While the intro-
duction of an ester group within the N(5) substituent offered no
improvement in aqueous kinetic solubility (70 and 71: 3.75 lM,
Table 5), N-benzoyl substituted derivative 72 showed reduced sol-
ubility (2.0 lM) compared to its unsubstituted counterpart, DIAS2
(7). However, the heterocycle-containing analogues, N-(5-isoxazol-
yl)carbonyl 81 and N-(1-morpholino)carbonyl 82 both showed
modestly improved solubility compared to DIAS2 (81: 6.5 lM;82: 10.5 lM, Table 5) demonstrating that through varying the
N(5)-substituent solubility could be improved within this series.
Adequate solubility is a highly desirable parameter for a range of
drug properties, and whilst some improvement was evident, fur-
ther optimisation is still required.63
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evaluation in vivo, it was also of interest to investigate the meta-
bolic stability of representative examples. To give an indication
of in vivo metabolic stability, the compounds were incubated
in vitro with mouse liver microsomes (MLM) and the concentration
monitored by mass spectrometry over time allowing a value for
half-life (t1/2) to be determined.64 Diazepam (t1/2 = 5–10 min) and
diphenhydramine (t1/2 = 30–40 min) were used as controls. A rep-
resentative selection of compounds were assessed using this
in vitro stability assay: S-benzyl derivatives 7 and 20, C(9)-bromo
substituted derivative 38, N-alkyl substituted derivatives 56–58,
N-benzyl analogue 59, N-sulfonyl analogue 62, and N-acyl deriva-
tives 67 and 72 (Table 5).
DIAS2 7 showed reasonable metabolic stability in the MLM
assay (t1/2 = 46 min): interestingly the S-oxidation product 26
was not detected amongst the metabolites. Replacing the
2-cyanobenzyl with a 2-nitrobenzyl group 20 did not signiﬁcantly
alter the stability (20: t1/2 = 43 min), whereas incorporating a
9-bromo substituent (38) led to a ten-fold reduction in half-life
(t1/2 = 5 min) compared to DIAS2 (7). The decreased stability of
38 may be due in part to its increased lipophilicity (c logP = 4.6):
in many instances more lipophilic compounds have been shown
to be better substrates for microsomal enzymes resulting in
increased turnover.65 All examples tested incorporating an N(5)
substituent showed a signiﬁcant reduction in stability, regardless
of the nature of the substituent: N-alkyl substituted derivatives
56–58, N-benzyl analogue 59, N-sulfonyl analogue 62, and N-acyl
derivative 67 all gave values for t1/2 of less than 5 min. In the case
of N-benzoyl derivative 72, no parent compound could be detected
at the earliest time point (5 min) precluding the determination of a
value for t1/2 and suggesting extremely rapid turnover. Impor-
tantly, the compounds were stable in the presence of microsomes
in the absence of added cofactor (NADPH), suggesting a micro-
somal enzyme-mediated degradation and, moreover, in all of the
studies carried out on the N(5)-substituted derivatives, DIAS2 (7)
was observed as the principal metabolite. This observation
suggested that the main origin of metabolic instability of the
N(5)-substituted derivatives was the lability of the exocyclic NAC
bond, independent of the nature of the linkage.2.8. DIAS2 (7) further evaluation
On the basis of the activity, afﬁnity, selectivity, solubility and
in vitro metabolic stability analyses DIAS2 (7) and 20were deemed
to possess the most promising overall proﬁles. The nitrile function-
ality within 7 was favoured over the nitro group within 20 due to
the well-documented possibility of toxicophores presented by the
nitro group upon degradation,66 and thus DIAS2 (7) was selected
for further evaluation.
It was of interest to investigate absorption properties of DIAS2
(7): ideally it was desired to generate an orally bioavailable com-
pound thatwould not accumulatewithin the CNS. To give an indica-
tion of cellular permeability and efﬂux, and in particular an
indication of whether signiﬁcant CNS penetration was likely,
Madin–Darby canine kidney cells transfected with multidrug resis-
tance protein 1 (MDCK-MDR1) were used as an in vitro model. This
cell line was selected as it can give an indication of p-glycoprotein-
mediated efﬂux, a major pathway through which compounds are
efﬂuxed within the gut and at the blood brain barrier (BBB). DIAS2
(7) was determined to have a permeability of 3.21  106 cm s1
predicting that the compound would be readily absorbed within
the gut. The efﬂux ratio was determined to be <1 indicating DIAS2
(7) is not a p-glycoprotein substrate. This permeability data also
predicts that the compound would be on the boundary of CNS
penetration.67It had already been demonstrated that DIAS2 (7) showed selec-
tivity for the CB2R over the CB1R (Table 1), but it was also of inter-
est to assess whether 7 also interacted with other targets,
particularly related GPCRs and also kinases. Thus, 7 was screened
for off-target activity against a selection of 24 GPCRs68 (Table S3)
and 97 kinases69 (Table S4). Kinases were of interest to measure
off target activity as they have been shown to bind polycyclic het-
eroaromatic structures, and as the cell-based activity screen mea-
sures intracellular cAMP levels it could in principle respond to a
compound interacting with other cellular components. The GPCR
screen used a radioligand displacement assay platform analogous
to the afﬁnity measurements at the CB1R and CB2R determined
previously. Encouragingly at a concentration of 1 lM, no signiﬁ-
cant binding was observed for 7 at any of the GPCRs tested
(Table S3), nor with any of the kinases when tested at a concentra-
tion of 10 lM (Table S4).69
3. Conclusions
In summary, a novel series of CB2R activating molecules has
been identiﬁed following a ligand-based screening approach using
a known CB2R agonist HU-308 as a template.
Systematical SAR analyses were conducted around the tricyclic
core, varying substituents at C(3), C(6)–C(9) and N(5). At C(3), thi-
obenzyl substituents incorporating small electron withdrawing
groups at the ortho site gave the highest levels of activity and afﬁn-
ity at the CB2R while maintaining selectivity over the CB1R. A small
substituent was also found to be tolerated at C(9), however this
was also found to give rise to modest afﬁnity at the CB1R. A range
of substituents were found to be tolerated at N(5), which allowed
tuning of the selectivity (e.g., N-benzyl 59: CB1R Ki = 61 nM, CB2R
Ki = 11 nM; N-benzoyl 72: CB1R Ki > 10,000 nM, CB2R Ki = 300 nM)
and, importantly, other molecular properties. While the introduc-
tion of polar groups within the substituent at N(5) was found to
improve solubility and reduce lipophilicity, all analogues examined
were rapidly metabolised in in vitro mouse liver microsome stabil-
ity studies: the major metabolite being DIAS2 (7) resulting from
cleavage of the exocyclic N(5)AC bond. The use of these analogues
as possible pro-drugs to liberate DIAS2 (7) in vivo is currently
being explored.
DIAS2 (7) was deemed to possess the most promising overall
proﬁle in terms of CB2R activity, afﬁnity, selectivity, lipophilicity
and in vitro metabolic stability and was therefore advanced to
further in vitro analyses. DIAS2 (7) was showed good in vitro
absorption properties and a low efﬂux ratio. Moreover, no signiﬁ-
cant off-target activity was observed when DIAS2 (7) was screened
against a panel of GPCRs and kinases. Overall we believe these
properties make DIAS2 (7) a promising candidate for further
investigation and application in vivo to assess the impact of CB2R
activity in inﬂammation (and other pathologies). A detailed study
of the formulation, in vivo pharmacokinetic properties, in vitro
and in vivo efﬁcacy of DIAS2 (7) in murine models of inﬂammation
will be imminently forthcoming.4. Experimental
4.1. General chemical methods
All reactions involving organometallic or moisture-sensitive
reagents were carried out under an argon atmosphere using stan-
dard vacuum line techniques and glassware that was ﬂame dried
and cooled under argon before use. Solvents were dried according
to the procedure outlined by Grubbs and co-workers.70 Water was
puriﬁed by an Elix UV-10 system. All other solvents and reagents
were used as supplied (analytical or HPLC grade) without prior
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ether refers to the fraction of petroleum spirit boiling between 30
and 40 C. Thin layer chromatography was performed on alumin-
ium plates coated with 60 F254 silica. Plates were visualised using
UV light (254 nM) or 1% aq KMnO4. Melting points were recorded
either on a Gallenkamp Hot Stage apparatus (Gallenkamp) or a
EZ-Melt Automated Melting Point Apparatus (EZ Melt) and are
uncorrected. IR spectra were recorded on a Bruker Tensor 27
FT-IR spectrometer with a diamond ATR module. Selected charac-
teristic peaks are reported in cm1. NMR spectra were recorded
on Bruker Avance spectrometers in the deuterated solvent stated.
The ﬁeld was locked by external referencing to the relevant
deuteron resonance. Chemical shifts (d) are reported in ppm and
coupling constants (J) are reported in Hz and are unaveraged.
Low-resolution mass spectra were recorded on either a VG
MassLab 20–250 or a Micromass Platform 1 spectrometer.
Accurate mass measurements were run on either a Bruker
MicroTOF internally calibrated with polyalanine, or a Micromass
GCT instrument ﬁtted with a Scientiﬁc Glass Instruments BPX5
column (15 m  0.25 mm) using amyl acetate as a lock mass,
by the mass spectrometry service of the Chemistry Research
Laboratory, University of Oxford, UK. HPLC analysis was carried
out on a Waters Xterra reverse phase C18 with gradients of water
(0.1% TFA) and acetonitrile (0.1% TFA).
4.2. General synthesis procedures
4.2.1. General procedure 1: S-substitution71
To a suspension of 5H-[1,2,4]triazino[5,6-b]indole-3-thiol (1
equiv) in methanol (5 mL) was added Et3N (1.5 equiv). To the
resulting suspension was added the requisite electrophile (1 equiv)
and the reaction mixture stirred at rt for 16 h. The resulting precip-
itate was ﬁltered and washed with a solution of Et3N in water
(1:25, 5% Et3N), which was dried in vacuo to yield the S-substituted
product which was puriﬁed as speciﬁed in each example below.
4.2.2. General procedure 2: N-substitution71
A ﬂask was ﬂame dried and cooled under an atmosphere of
argon. To the ﬂask was added the S-substituted-5H-[1,2,4]triazi-
no[5,6-b]indole-3-thiol (1 equiv) and anhydrous DMF or THF
(5 mL) under argon. The resulting suspension was cooled to 0 C
using an ice bath. NaH (60% dispersion in mineral oil, 1.1–1.5
equiv) was added, resulting in a clear yellow solution, which was
stirred for 15 min at 0 C. The corresponding electrophile (1.5
equiv) was added gradually (dropwise or portionwise) at 0 C. After
addition was complete, the reaction mixture was allowed to warm
to rt and stirred for 16 h under argon. The reaction was quenched
with water and the product extracted as speciﬁed below.
4.3. Chemical synthesis
4.3.1. 5H-[1,2,4]Triazino[5,6-b]indole-3-thiol (9)50
To a stirred suspension of isatin 8 (5.00 g, 33.2 mmol) and
K2CO3 (7.05 g, 51.0 mmol) in water (100 mL), was added thiosem-
icarbazide (3.09 g, 33.2 mmol). The mixture was heated under
reﬂux for 16 h. Upon cooling the solution was acidiﬁed with glacial
acetic acid to afford a precipitate, which was ﬁltered and washed
with a water/acetic acid (24:1, v/v) mixture. The resulting solid
was triturated with hot DMF, ﬁltered and dried to yield the product
(9) as a yellow solid (6.25 g, 92%); mp (Gallenkamp) >300 C [lit.50
mp >300 C]; dH (400 MHz, DMSO-d6, 363 K) 7.34 (1H, app t,
J = 7.6 Hz, C(8)H), 7.44 (1H, d, J = 8.1 Hz, C(6)H), 7.62 (1H, app t,
J = 7.6 Hz, C(7)H), 8.00 (1H, d, J = 7.6 Hz, C(9)H); dC (100 Hz,
DMSO-d6) 113.9, 118.6, 122.7, 123.9, 132.7, 136.5, 144.0, 150.0,
179.9; m/z (ESI) 201 ([MH], 100%).4.3.2. 3-(Methylthio)-5H-[1,2,4]triazino[5,6-b]indole (10)
Methyl iodide (308 lL, 4.95 mmol) was added to a stirred solu-
tion on 5H-[1,2,4]triazino[5,6-b]indole-3-thiol 9 (1.0 g, 4.95 mmol)
and K2CO3 (683 mg, 4.95 mmol) and stirred at rt for 16 h during
which time the yellow solution turned green. The solvent was
removed in vacuo to yield the product (10) as a light green solid
(1.01 g, 95%); mp (EZ Melt) >300 C; mmax (solid) 3056, 2799,
1600, 1576, 1460, 1415, 1232; HPLC (Method 2) >99%, tR = 11.31;
dH (400 MHz, DMSO-d6, 363 K) 2.66 (3H, s, CH3), 7.43 (1H, app td,
J = 8.2, 1.0 Hz, C(8)H), 7.58 (1H, app dd, J = 8.2, 1.0 Hz, C(6)H),
7.67–7.71 (1H, m, C(7)H), 8.31 (1H, app dd, J = 8.2, 1.0 Hz, C(9)H),
12.60 (1H, br s, NH); dC (100 MHz, DMSO-d6) 13.4, 112.7, 117.7,
121.4, 122.4, 130.8, 140.3, 140.8, 146.7, 167.6; m/z (ESI) 215
([MH], 100%); HRMS (ESI+) C10H8N4NaS ([M+Na]+) requires
239.0362; found 239.0360.
4.3.3. 3-(Butylthio)-5H-[1,2,4]triazino[5,6-b]indole (6, DIAS 1)
To a suspension of 5H-[1,2,4]triazino[5,6-b]indole-3-thiol 9
(80 mg, 0.40 mmol) and Cs2CO3 (194 mg, 0.94 mmol) in methanol
(10 mL) was added iodobutane (45 lL, 0.4 mmol) and the resulting
mixture stirred for 16 h at 80 C to afford a yellow solution. Upon
cooling, the solvents were removed in vacuo and resulting solid
was washed with water/methanol to yield the title compound (6,
DIAS1) as a yellow solid (82 mg, 80%); mp (Gallenkamp) 249–
252 C; mmax (solid) 3058, 2957, 2802, 1607, 1461, 1186; HPLC
(Method 2) >99%, tR = 10.73 min; dH (400 MHz, DMSO-d6, 363 K)
0.94 (3H, t, J = 7.3 Hz, C(40)H), 1.42–1.53 (2H, m, C(30)H), 1.71–
1.77 (2H, m, C(20)H), 3.28 (2H, t, J = 7.7 Hz, C(10)H), 7.44 (1H, app
t, J = 7.9 Hz, C(8)H), 7.57 (1H, d, J = 8.2 Hz, C(6)H), 7.66–7.72 (1H,
m, C(7)H), 8.30 (1H, d, J = 7.9 Hz, C(9)H); dC (100 MHz, DMSO-d6)
13.5, 21.5, 29.6, 30.9, 112.7, 117.7, 121.4, 122.4, 130.7, 140.3,
140.9, 146.7, 167.3; m/z (ESI+) 281 ([M+Na]+, 100%); HRMS (ESI+)
C13H14N4NaS ([M+Na]+) requires 281.0831; found 281.0821.
4.3.4. 3-((Cyclohexylmethyl)thio)-5H-[1,2,4]triazino[5,6-
b]indole (11)
Following General procedure 1, to 5H-[1,2,4]triazino[5,6-
b]indole-3-thiol 9 (150 mg, 0.74 mmol) and Et3N (155 lL,
1.11 mmol) in methanol (5 mL) was added bromomethyl cyclohex-
ane (104 lL, 0.74 mmol) and the resulting suspension was stirred
at rt for 16 h. The precipitate was ﬁltered and washed to give the
title compound (11) as a pale yellow solid (149 mg, 67%); mp (Gal-
lenkamp) 298–300 C; mmax (solid) 3059, 2918, 1603, 1582, 1460,
1420, 1336; HPLC (Method 1) >95%, tR = 11.62 min; dH (400 MHz,
DMSO-d6, 363 K) 1.04–1.25 (5H, m, 5 CH), 1.63–1.73 (4H, m, 4
CH), 1.87–1.91 (2H, m, 2 CH), 3.20 (2H, d, J = 6.7 Hz, S-CH2),
7.43 (1H, app t, J = 7.6 Hz, C(7)H), 7.57 (1H, d, J = 7.6 Hz, C(6)H),
7.69 (1H, app t, J = 7.6 Hz, C(8)H), 8.30 (1H, d, J = 7.6 Hz, C(9)H),
12.60 (1H, br s, NH); dC (100 MHz, DMSO-d6) 25.5, 25.8, 32.1,
36.7, 37.1, 112.6, 117.7, 121.4, 122.4, 130.8, 140.2, 140.9, 146.6,
167.5; m/z (ESI) 297 ([MH], 100%); HRMS (ESI+) C16H18N4NaS
([M+Na]+) requires 321.1144; found 321.1143.
4.3.5. 3-(Benzylthio)-5H-[1,2,4]triazino[5,6-b]indole (12)
To an aqueous solution of NaOH (4%, 5.00 mL) was added 5H-
[1,2,4]triazino[5,6-b]indole-3-thiol 9 (100 mg, 0.49 mmol) fol-
lowed by benzyl bromide (58.5 lL, 0.49 mmol). The reaction was
stirred at overnight at rt and resulting precipitate was ﬁltered.
Recrystallisation from methanol yielded the product (12) as a light
yellow solid (68 mg, 75%); mp (Gallenkamp) 290–292 C; mmax
(solid) 3059, 2799, 1600, 1579, 1461, 1321; HPLC (Method 1)
>99%, tR = 11.06 min; dH (400 MHz, DMSO-d6) 4.57 (2H, s, CH2),
7.27 (1H, t, J = 7.9 Hz, C(40)H), 7.34 (2H, app t, J = 7.6 Hz, C(30)H
and C(50)H), 7.44 (1H, app t, J = 7.7 Hz, C(8)H), 7.52 (2H, d,
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(1H, app t, J = 7.7 Hz, C(7)H), 8.31 (1H, d, J = 7.7 Hz, C(9)H), 12.66
(1H, br s, NH); dC (126 Hz, DMSO-d6) 34.0, 112.7, 117.6, 121.5,
122.5, 127.2, 128.5, 129.1, 130.9, 137.6, 140.3, 141.1, 146.6,
166.7; m/z (ESI) 291 ([MH], 100%); HRMS (ESI+) C16H12NaN4S
([M+Na]+) requires 315.0675; found 315.0663.
4.3.6. 3-((20-Cyanobenzyl)thio)-5H-[1,2,4]triazino[5,6-b]indole
(7, DIAS2)
Following General procedure 1, to 5H-[1,2,4]triazino[5,6-
b]indole-3-thiol 9 (2.26 g, 11.2 mmol) and Et3N (2.33 mL,
16.8 mmol) in methanol (40 mL) was added 2-cyanobenzyl bro-
mide (2.19 g, 11.2 mmol) and the resulting mixture stirred at rt
for 16 h. The precipitate was ﬁltered and washed to give the title
compound (7, DIAS2) as a pale yellow solid (3.60 g, quant); mp
(Gallenkamp) 276–278 C; mmax (solid) 3061, 2971, 2804, 2226,
1598, 1580, 1342; HPLC (Method 1) >99%, tR = 10.85 min; dH
(400 MHz, DMSO-d6, 363 K) 4.73 (2H, s, CH2), 7.41–7.49 (2H, m,
C(8)H and C(40)H), 7.58 (1H, d, J = 7.8 Hz, C(60)H), 7.64–7.71 (2H,
m, C(30)H and C(7)H), 7.82 (1H, m, C(50)H), 7.85 (1H, d, J = 7.6 Hz,
C(6)H), 8.30 (1H, d, J = 7.8 Hz, C(9)H), 12.66 (1H, br s, NH); dC
(100 MHz, DMSO-d6) 32.4, 111.9, 112.6, 117.3, 117.4, 121.4,
122.4, 128.1, 130.2, 130.9, 133.0, 133.2, 140.2, 141.1, 141.2,
146.4, 165.6; m/z (ESI) 316 ([MH], 100%); HRMS (ESI+) C17H10
N5S ([MH]) requires 316.0662; found 316.0673.
4.3.7. 3-((30-Cyanobenzyl)thio)-5H-[1,2,4]triazino[5,6-b]indole
(13)
Following General procedure 1, to 5H-[1,2,4]triazino[5,6-
b]indole-3-thiol 9 (150 mg, 0.74 mmol) and Et3N (155 lL,
1.11 mmol) in methanol (5 mL) was added 3-cyano benzyl bromide
(146 mg, 0.74 mmol) and the resulting mixture was stirred over-
night. The precipitate was ﬁltered and washed to give the title com-
pound (13) as a pale yellow solid (137 mg, 58%); mp (Gallenkamp)
279–281 C; C17H11N5S requires C, 64.34; H, 3.49; N, 22.07; found
C, 64.07; H, 3.33; N, 22.02; mmax (solid) 3120, 2228, 1596, 1579,
1338, 1173; dH (400 MHz, DMSO-d6, 363 K) 4.62 (2H, s, CH2), 7.44
(1H, app t, J = 7.6 Hz, C(8)H), 7.55 (1H, app t, J = 7.6 Hz, C(50)H),
7.59 (1H, app t, J = 7.6 Hz, C(6)H), 7.70 (1H, app t, J = 7.6 Hz,
C(7)H), 7.72–7.75 (1H, m, C(60)H), 7.90 (1H, d, J = 8.2 Hz, C(40)H),
7.99 (1H, s, C(20)H), 8.32 (1H, d, J = 7.6 Hz, C(9)H), 12.67 (1H, br s,
NH); dC (100 MHz, DMSO-d6) 33.1, 111.3, 112.7, 117.6, 118.7,
121.5, 122.5, 129.7, 131.0, 131.0, 132.5, 134.0, 139.9, 140.3, 141.3,
146.6, 166.1;m/z (ESI) 316 ([MH], 100%); HRMS (ESI+) C17H11N5
NaS ([M+Na]+) requires 340.0627; found 340.0619.
4.3.8. 3-((20-Fluorobenzyl)thio)-5H-[1,2,4]triazino[5,6-b]indole
(14)
To an aqueous solution of NaOH (4%, 5 mL) was added 5H-
[1,2,4]triazino[5,6-b]indole-3-thiol 9 (150 mg, 0.74 mmol) and 2-
ﬂuoro benzyl bromide (89.6 lL, 0.74 mmol) and the reaction was
stirred overnight at rt. The resulting precipitate was ﬁltered and
recrystallised from methanol to yield the title compound (14) as
a light yellow solid (131 mg, 57%); mp (Gallenkamp) 285–286 C;
mmax (solid) 3054, 2800, 1492, 1461, 1323, 1176; HPLC (Method
1) 97.0%, tR = 11.13 min; dH (400 MHz, DMSO-d6) 4.59 (2H, s,
CH2), 7.16 (1H, app t, J = 7.6 Hz, C(50)H), 7.21–7.24 (1H, m,
C(60)H), 7.32–7.35 (1H, m, C(30)H), 7.43 (1H, app t, J = 7.6 Hz,
C(8)H), 7.58 (1H, d, J = 7.6 Hz, C(6)H), 7.65 (1H, app t, J = 7.6 Hz,
C(40)H), 7.69 (1H, app t, J = 7.6 Hz, C(7)H), 8.30 (1H, d, J = 7.6 Hz,
C(9)H), 12.67 (1H, br s, NH); dC (126 Hz, DMSO-d6) 27.6, 112.7,
115.4 (d, J = 21 Hz), 117.6, 121.5, 122.5, 124.3 (d, J = 14 Hz),
124.5, 129.5 (d, J = 8 Hz) 130.9, 131.4 (d, J = 4 Hz), 140.3, 141.2,
146.6, 160.6 (d, J = 246 Hz), 166.3; dF (470 MHz, DMSO-d6)
116.6; m/z (ESI) 309 ([MH], 100%); HRMS (ESI+) C16H11FNaN4
S ([M+Na]+) requires 333.0581; found 333.0572.4.3.9. 3-((40-Fluorobenzyl)thio)-5H-[1,2,4]triazino[5,6-b]indole
(15)
To an aqueous solution of NaOH (4%, 5 mL) was added 5H-
[1,2,4]triazino[5,6-b]indole-3-thiol 9 (150 mg, 0.74 mmol) and
2-ﬂuoro benzyl bromide (92.5 lL, 0.74 mmol). The reaction was
stirred overnight at rt and resulting precipitate was ﬁltered.
Recrystallisation from methanol yielded the title compound (15)
as a light yellow solid (187 mg, 82%); mp (Gallenkamp) 261–
264 C; mmax (solid) 3054, 2798, 1600, 1539, 1461, 1417; HPLC
(Method 1) >97%, tR = 11.11 min; dH (400 MHz, DMSO-d6, 363 K)
4.56 (2H, s, CH2), 7.15 (2H, app t, J = 8.8 Hz, C(30)H and C(50)H),
7.42 (1H, app t, J = 7.9 Hz, C(8)H), 7.56 (1H, d, J = 7.9 Hz, C(6)H),
7.57 (2H, d, J = 7.9 Hz, C(20)H and C(60)H), 7.68 (1H, app t,
J = 7.9 Hz, C(7)H), 8.29 (1H, d, J = 7.9 Hz, C(9)H), 12.64 (1H, br s,
NH); dC (100 Hz, DMSO-d6) 33.2, 112.7, 115.2 (d, J = 21 Hz), 117.6,
121.5, 122.4, 130.9, 131.0 (d, J = 8 Hz), 133.9 (d, J = 3 Hz), 140.3,
141.1, 146.6, 161.3 (d, J = 243 Hz), 166.5; dF (470 MHz, DMSO-d6)
115.3; m/z (ESI) 309 ([MH], 100%); HRMS (ESI+) C16H11
FN4NaS ([M+Na]+) requires 333.0581; found 333.0576.
4.3.10. 3-((20,60-Diﬂuorobenzyl)thio)-5H-[1,2,4]triazino[5,6-
b]indole (16)
Following General procedure 1, to 5H-[1,2,4]triazino[5,6-
b]indole-3-thiol 9 (150 mg, 0.74 mmol) and Et3N (155 lL,
1.11 mmol) in methanol (5 mL), was added 2,6-diﬂuoro benzyl
bromide (154 mg, 0.74 mmol) and the resulting mixture was stir-
red at rt for 16 h. The precipitate was ﬁltered and washed to give
the title compound (16) as a pale yellow solid (132 mg, 54%); mp
(Gallenkamp) 292–294 C; mmax (solid) 3065, 2968, 2802, 1626,
1594, 1578, 1470, 1343; HPLC (Method 1) >97%, tR = 11.28 min;
dH (400 MHz, DMSO-d6, 363 K) 4.66 (2H, s, CH2), 7.14–7.18 (2H,
m, C(30)H and C(50)H), 7.42–7.46 (2H, m, C(8)H and C(40)H), 7.59
(1H, d, J = 7.9 Hz, C(6)H), 7.71 (1H, app t, J = 7.9 Hz, C(7)H), 8.33
(1H, d, J = 7.9 Hz, C(9)H), 12.69 (1H, br s, NH); dC (100 Hz, DMSO-
d6) 21.7, 111.8 (dd, J = 20, 5 Hz), 112.7, 112.8, 117.6, 121.6, 122.5,
130.2 (t, J = 11 Hz), 131.0, 140.4, 141.3, 146.6, 160.9 (dd, J = 248,
7.6 Hz), 166.0; dF (470 MHz, DMSO-d6) 113.1; m/z (ESI) 327
([MH], 100%); HRMS (ESI) C16H9F2N4S ([MH]) requires
327.0521; found 327.0536.
4.3.11. 3-((20-Chlorobenzyl)thio)-5H-[1,2,4]triazino[5,6-b]indole
(17)
Following General procedure 1, to 5H-[1,2,4]triazino[5,6-
b]indole-3-thiol 9 (150 mg, 0.74 mmol) and Et3N (155 lL,
1.11 mmol) in methanol (5 mL) was added 2-chloro benzyl bro-
mide (97 lL, 0.74 mmol) and the resulting mixture stirred at rt
for 16 h. The precipitate was ﬁltered and washed to give the title
compound (17) as a pale yellow solid (190 mg, 79%); mp (Gallenk-
amp) 266–267 C; mmax (solid) 3026, 2973, 2804, 1599, 1580, 1342,
1177; HPLC (Method 1) >99%, tR = 11.44 min; dH (400 MHz, DMSO-
d6, 363 K) 4.67 (2H, s, CH2), 7.32–7.36 (2H, m, C(8)H and C(60)H),
7.43–7.46 (1H, m, C(7)H), 7.49–7.53 (1H, m, C(40)H), 7.59 (1H, d,
J = 8.2 Hz, C(6)H), 7.70 (1H, d, J = 7.6 Hz, C(30)H), 7.72–7.74 (1H,
m, C(50)H), 8.32 (1H, d, J = 7.6 Hz, C(9)H), 12.69 (1H, br s, NH); dC
(100 MHz, DMSO-d6) 32.1, 112.7, 117.6, 121.5, 122.5, 127.4,
129.3, 129.5, 131.0, 131.5, 133.4, 134.9, 140.4, 141.3, 146.6,
166.3;m/z (ESI) 325 ([MH], 100%); HRMS (ESI+) C16H10ClNaN4S
([35ClM+Na]+) requires 349.0285; found 349.0286, C16H10ClNaN4S
([37ClM+Na]+) requires 351.0256; found 351.0262.
4.3.12. 3-((30-Chlorobenzyl)thio)-5H-[1,2,4]triazino[5,6-b]indole
(18)
Following General procedure 1, to 5H-[1,2,4]triazino[5,6-
b]indole-3-thiol 9 (150 mg, 0.74 mmol) and Et3N (155 lL,
1.11 mmol) in methanol (5 mL) was added 3-chloro benzyl bro-
mide (97 lL, 0.74 mmol) and the resulting mixture stirred at rt
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compound (18) as a very pale yellow solid (175 mg, 73%); mp
(Gallenkamp) 266–267 C; mmax (solid) 3059, 2799, 1597, 1574,
1461, 1336; HPLC (Method 2) >99%, tR = 11.54 min; dH (400 MHz,
DMSO-d6, 363 K) 4.58 (2H, s, CH2), 7.31–7.34 (1H, m, C(60)H),
7.36 (1H, t, J = 7.6 Hz, C(50)H), 7.44 (1H, app t, J = 7.6 Hz, C(8)H),
7.51 (1H, app d, J = 7.6 Hz, C(40)H), 7.57–7.62 (2H, m, C(6)H and
C(10)H), 7.70 (1H, app t, J = 7.6 Hz, C(7)H), 8.31 (1H, d, J = 7.6, Hz
C(9)H), 12.67 (1H, br s, NH); dC (100 MHz, DMSO-d6) 33.3, 112.7,
117.6, 121.5, 122.5, 127.1, 127.8, 128.8, 130.3, 131.0, 132.9,
140.3, 140.5, 141.2, 146.6, 166.3; m/z (ESI) 325 ([MH], 100%);
HRMS (ESI+) C16H1035ClN4S ([MH]) requires 325.0320; found
325.0330, C16H1037ClN4S ([MH]) requires 327.0291; found
327.0306.
4.3.13. 3-((40-Chlorobenzyl)thio)-5H-[1,2,4]triazino[5,6-b]indole
(19)
Following General procedure 1, to 5H-[1,2,4]triazino[5,6-
b]indole-3-thiol 9 (150 mg, 0.74 mmol) and Et3N (155 lL,
1.11 mmol) in methanol (5 mL) was added 3-chloro benzyl bro-
mide (152 mg, 0.74 mmol) and the resulting mixture stirred at rt
for 16 h. The precipitate was ﬁltered and washed to give the title
compound (19) as a pale yellow solid (142 mg, 59%); mp
(Gallenkamp) 248–250 C; mmax (solid) 3054, 2797, 1600, 1578,
1489, 1461, 1338; HPLC (Method 1) >98%, tR = 11.51 min; dH
(400 MHz, DMSO-d6, 363 K) 4.56 (2H, s, CH2), 7.38, (2H, d,
J = 8.8 Hz, C(20)H and C(60)H), 7.44 (1H, app t, J = 7.6 Hz, C(8)H),
7.55 (2H, d, J = 8.8 Hz, C(30)H and C(50)H), 7.58 (1H, d, J = 7.6 Hz,
C(6)H), 7.70 (1H, app t, J = 7.6 Hz, C(7)H), 8.31 (1H, d, J = 7.6 Hz,
C(9)H), 12.66 (1H, br s, NH); dC (100 MHz, DMSO-d6) 33.2, 112.7,
117.6, 121.5, 122.5, 128.4, 128.6, 130.9, 131.8, 137.0, 140.3,
141.2, 146.6, 166.4; m/z (ESI) 325 ([35ClMH], 100%), 327
([37ClMH], 45%); HRMS (ESI+) C16H1035ClNaN4S ([M+H]+) requires
349.0285; found 349.0284, C16H1037ClNaN4S ([M+H]+) requires
351.0256; found 351.0258.
4.3.14. 3-((20-Nitrobenzyl)thio)-5H-[1,2,4]triazino[5,6-b]indole
(20)
Following General procedure 1, to 5H-[1,2,4]triazino[5,6-
b]indole-3-thiol 9 (150 mg, 0.74 mmol), and Et3N (155 lL,
1.11 mmol) in methanol (5 mL) was added 2-nitrobenzyl bromide
(160 mg, 0.74 mmol) and the resulting mixture stirred at rt for
16 h. The resulting precipitate was ﬁltered and washed to give
the title compound (20) as a pale yellow solid (246 mg, 98%); mp
(Gallenkamp) 264–265 C; mmax (solid) 3066, 2965, 2793, 1602,
1524, 1336; C16H11N5O2S requires C, 56.96; H, 3.29; N, 20.76;
found C, 56.75; H, 3.16; N, 20.55; dH (400 MHz, DMSO-d6, 363 K)
4.87 (2H, s, CH2), 7.40–7.43 (1H, m, C(8)H), 7.55 (1H, app t,
J = 7.3 Hz, C(40)H), 7.58 (1H, d, J = 7.3 Hz, C(6)H), 7.66–7.72 (2H,
m, C(7)H and C(50)H), 7.91 (1H, dd, J = 7.3, 1.3 Hz, C(60)H), 8.05
(1H, d, J = 7.3 Hz, C(30)H), 8.98 (1H, d, J = 7.3 Hz, C(9)H), 12.62
(1H, bs, NH); dC (100 Hz, DMSO-d6) 31.1, 112.4, 117.5, 121.5,
122.5, 124.9, 128.9, 131.0, 132.5, 133.1, 133.7, 140.4, 141.3,
146.5, 148.4, 166.0; m/z (ESI) 336 ([MH], 100%); HRMS (ESI+)
C16H11NaN5O2S ([M+Na]+) requires 360.0526; found 360.0516.
4.3.15. 3-((40-Nitrobenzyl)thio)-5H-[1,2,4]triazino[5,6-b]indole
(21)
Following General procedure 1, to 5H-[1,2,4]triazino[5,6-
b]indole-3-thiol 9 (150 mg, 0.74 mmol), and Et3N (155 lL,
1.11 mmol) in methanol (15 mL) was added 4-nitrobenzyl bromide
(160 mg, 0.74 mmol) and the resulting mixture stirred at rt for
16 h. The resulting precipitate was ﬁltered and washed to give
the title compound (21) as a light yellow solid (97 mg, 62%); mp
(EZ Melt) 235–237 C; mmax (solid) 3455, 3336, 1680, 1584, 1466,
1438; HPLC (Method 2) >99%, tR = 11.09 min; dH (500 MHz,DMSO-d6, 363 K) 4.69 (2H, s, CH2), 7.43 (1H, app t, J = 7.6 Hz,
C(8)H), 7.58 (1H, d, J = 7.6 Hz, C(6)H), 7.70 (1H, app td, J = 7.6,
1.3 Hz, C(7)H), 7.81 (2H, d, J = 8.8 Hz, C(20)H and C(60)H), 8.18
(2H, d, J = 8.8 Hz, C(30)H and C(50)H), 8.30 (1H, d, J = 7.6 Hz,
C(9)H), 12.66 (1H, s, NH); dC (125 MHz, DMSO-d6) 33.6, 113.1,
117.9, 121.9, 122.9, 123.8, 130.6, 131.4, 140.7, 141.7, 146.7,
146.9, 146.9, 166.3; m/z (ESI) 336 ([MH], 100%); HRMS (ESI+)
C16H11NaN5O2S ([M+Na]+) requires 360.0526; found 360.0516.
4.3.16. 3-((20-(Triﬂuoromethyl)benzyl)thio)-5H-
[1,2,4]triazino[5,6-b]indole (22)
Following General procedure 1, to 5H-[1,2,4]triazino[5,6-
b]indole-3-thiol 9 (150 mg, 0.74 mmol) and Et3N (155 lL,
1.11 mmol) in methanol (5 mL) was added 2-triﬂuoromethyl ben-
zyl bromide (176 mg, 0.74 mmol) and the resulting mixture was
stirred at rt for 16 h. The precipitate was ﬁltered and washed to
give the title compound (22) as a pale yellow solid (196 mg,
74%); mp (Gallenkamp) 269–270 C; mmax (solid) 3061, 2970,
2804, 1739, 1600, 1581, 1299; HPLC (Method 1) >99%, tR = 11.71 -
min; dH (400 MHz, DMSO-d6, 363 K) 4.76 (2H, s, CH2), 7.41–7.47
(1H, m, C(8)H)), 7.49–7.55 (1H, m, C(7)H), 7.59 (1H, d, J = 8.2 Hz,
C(60)H), 7.63–7.72 (2H, m, C(50) and C(40)H), 7.78 (1H, d,
J = 7.9 Hz, C(30)H), 7.87 (1H, d, J = 7.9 Hz, C(6)H), 8.32 (1H, d,
J = 7.9 Hz, C(9)H), 12.68 (1H, br s, NH); dC (100 Hz, DMSO-d6)
32.5, 112.7, 117.5, 121.6, 122.5, 123.0, 128.2, 130.4, 131.0, 132.1
(q, J = 284 Hz), 133.1, 133.3, 140.4, 141.4, 146.5, 149.1, 165.7; dF
(470 MHz, DMSO-d6) 58.1;m/z (ESI) 359 ([MH], 100%); HRMS
(ESI) C17H10F3N4S ([MH]) requires 359.0584; found 359.0595.
4.3.17. 3-((20-(Triﬂuoromethoxy)benzyl)thio)-5H-
[1,2,4]triazino[5,6-b]indole (23)
Following General procedure 1, to 5H-[1,2,4]triazino[5,6-
b]indole-3-thiol 9 (150 mg, 0.74 mmol) and Et3N (155 lL,
1.11 mmol) in methanol (5 mL) was added 2-(triﬂuorometh-
oxy)benzyl bromide (119 lL, 0.74 mmol) and the resulting mixture
stirred was stirred at rt for 16 h. The precipitate was washed to
give the title compound (23) as a pale yellow solid (139 mg,
50%); mp (Gallenkamp) 285–288 C; mmax (solid) 3062, 2969,
2805, 1607, 1461, 1423; HPLC (Method 1) >99%, tR = 11.70 min;
dH (400 MHz, DMSO-d6, 363 K) 4.64 (2H, s, CH2), 7.36–7.39 (1H,
m, C(40)H), 7.39–7.47 (3H, m, C(8)H, C(50)H and C(60)H), 7.60 (1H,
d, J = 7.9 Hz, C(6)H), 7.71 (1H, app t, J = 7.9 Hz, C(7)H), 7.76 (1H,
dd, J = 7.6, 1.6 Hz, C(30)H), 8.32 (1H, d, J = 7.9 Hz, C(9)H), 12.67
(1H, br s, NH); dC (100 MHz, DMSO-d6) 28.4, 112.7, 117.6, 120.2
(q, J = 257 Hz), 120.4, 121.5, 122.5, 127.5, 129.5, 129.9, 131.0,
131.7, 140.4, 141.3, 146.6, 146.9, 166.1; dF (470 MHz, DMSO-d6)
55.9; m/z (ESI) 375 ([MH], 100%); HRMS (ESI+) C17H11F3N4
NaOS ([M+Na]+) requires 399.0498; found 399.0499.
4.3.18. Ethyl 20-(((5H-[1,2,4]triazino[5,6-b]indol-3-
yl)thio)methyl)benzoate (24)
Following General procedure 1, to 5H-[1,2,4]triazino[5,6-
b]indole-3-thiol 9 (200 mg, 0.99 mmol) and Et3N (303 lL,
2.18 mmol) in methanol (10 mL) was added ethyl 2-(bromo-
methyl)benzoate (361 mg, 1.53 mmol) and the resulting mixture
stirred at rt for 16 h. The resulting precipitate was washed to give
the title compound (24) as a pale yellow solid (436 mg, 83%); mp
(Gallenkamp) 205–206 C; mmax (solid) 3151, 2989, 1707, 1597,
1250, 1079; HPLC (Method 2) >95%, tR = 11.36 min; dH (400 MHz,
DMSO-d6, 363 K) 1.31 (3H, t, J = 7.0 Hz, CH3), 4.34 (2H, q,
J = 7.0 Hz, O-CH2–CH3), 4.88 (2H, s, S-CH2), 7.37–7.45 (2H, m,
C(8)H and C(50)H), 7.53 (1H, app t, J = 7.7 Hz, C(7)H), 7.57 (1H, d,
J = 7.7 Hz, C(6)H), 7.63–7.70 (1H, m, C(40)H), 7.75 (1H, d,
J = 7.7 Hz, C(60)H), 7.88 (1H, dd, J = 7.8, 1.3 Hz, C(30)H), 8.29 (1H,
d, J = 7.8 Hz, C(9)H), 12.62 (1H, s, NH); dC (100 MHz, DMSO-d6)
14.9, 33.4, 61.8, 113.6, 118.5, 122.3, 123.3, 128.5, 130.3, 131.4,
M. Gianella-Borradori et al. / Bioorg. Med. Chem. 23 (2015) 241–263 253131.7, 132.4, 133.1, 140.0, 141.2, 142.0, 147.4, 167.5, 167.7; m/z
(ESI) 363 ([MH], 100%); HRMS (ESI) C19H15N4O2S ([MH])
requires 363.0921; found 363.0927.
4.3.19. 20(((5H-[1,2,4]Triazino[5,6-b]indol-3-
yl)thio)methyl)benzoic acid (25)
Ethyl 20-(((5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio)methyl)ben-
zoate 24 (100 mg, 0.27 mmol), was added to a solution of aq NaOH
(1 M, 270 lL, 0.27 mmol) in H2O (5 mL) and stirred at rt for 16 h.
The solution was acidiﬁed with aq HCl (1 M) until a precipitate
was formed, which was ﬁltered and dried in vacuo to yield the ﬁnal
product (25) (92 mg, 99%); mp (Gallenkamp) >300 C; mmax (solid)
3241 (v br), 1712, 1553, 1378, 1166, 1090; HPLC (Method 2) >99%,
tR = 10.11 min; dH (500 MHz, DMSO-d6, 363 K) 4.99 (2H, s, S-CH2),
7.12–7.22 (3H, m, C(7)H, C(8)H and C(40)H), 7.47–7.52 (3H, m,
C(6)H, C(50)H and C(60)H), 7.68–7.72 (1H, m, C(30)H), 8.15 (1H, d,
J = 7.6 Hz, C(9)H); dC (125 MHz, DMSO-d6) 32.1, 114.9, 119.1,
119.7, 120.7, 126.0, 127.4, 129.2, 129.5, 129.6, 130.0, 137.2,
141.1, 142.5, 150.4, 166.4, 171.6; m/z (ESI) 335 ([MH], 100%);
HRMS (ESI) C17H11N4O2S ([MH]) requires 335.0608; found
335.0612.
4.3.20. 2-(((5H-[1,2,4]Triazino[5,6-b]indol-3-
yl)sulﬁnyl)methyl)benzonitrile (26)
20-(((5H-[1,2,4]Triazino[5,6-b]indol-3-yl)thio)methyl)benzoni-
trile 7 (50 mg, 0.16 mmol) was added to a solution of triﬂuoroace-
tic acid (5 mL) and peroxytriﬂuoroacetic acid (4 M, 40 lL,
0.16 mmol) and stirred for 16 h at rt. The resulting solution was
concentrated in vacuo to yield the sulfoxide (26) as a yellow solid
(50 mg, 95%); mp (EZ Melt) 237–239 C; mmax (solid) 3244, 2228,
1621, 1591, 1570, 1416, 1183; HPLC (Method 2) >96%,
rt = 9.22 min; dH (500 MHz, DMSO-d6, 363 K) 4.64 (1H, d, J = 13.2,
S-CH2), 4.81 (1H, d, J = 13.2 Hz, S-CH2), 7.43 (1H, d, J = 7.6 Hz,
C(6)H), 7.52 (1H, app td, J = 7.6, 1.3 Hz, C(8)H), 7.55 (1H, app t,
J = 7.6 Hz, C(50)H), 7.65 (1H, app td, J = 7.6, 1.3 Hz, C(7)H), 7.72
(1H, d, J = 7.6 Hz, C(30)H), 7.80 (1H, dd, J = 7.6, 1.0 Hz, C(60)H),
7.84 (1H, app t, J = 7.6, 1.3 Hz, C(40)H), 8.48 (1H, d, J = 7.6 Hz,
C(9)H), 13.19 (1H, br s, NH); dC (125 MHz, DMSO-d6) 57.7, 112.9,
113.2, 117.0, 117.2, 122.6, 123.1, 129.0, 132.1, 132.5, 133.1,
133.1, 133.2, 141.7, 144.5, 147.1, 166.5; m/z (ESI) 332 ([MH],
100%); HRMS (ESI+) C17H11N5NaOS ([M+Na]+) requires 356.0577;
found 356.0571.
4.3.21. 6-Bromo-5H-[1,2,4]triazino[5,6-b]indole-3-thiol (31)
7-Bromoisatin 27 (1.00 g, 4.45 mmol), thiosemicarbazide
(405 mg, 4.45 mmol) and K2CO3 (920 mg, 6.67 mmol) were sus-
pended in water (50 mL). The reaction mixture was stirred at reﬂux
for 16 h over which time the dark brown suspension became a
clear light brown solution. The solution was carefully acidiﬁed by
dropwise addition of acetic acid and the resulting precipitate was
ﬁltered. The precipitate was recrystallised from DMF to yield the
title compound (31) as a red solid (416 mg, 34%); mp (Gallenkamp)
>300 C; mmax (solid) 2849 (br), 1629, 1603, 1581, 1386, 1151; dH
(500 MHz, DMSO-d6, 363 K) 7.28 (1H, app t, J = 7.6 Hz, C(8)H),
7.84 (1H, d J = 7.6 Hz, C(7)H), 8.01 (1H, d, J = 7.6 Hz, C(9)H); dC
(125 MHz, DMSO-d6) 116.1, 117.5, 123.8, 124.9, 126.3, 135.5,
144.6, 149.9, 176.6; m/z (ESI) 279 ([79BrMH], 100%), 281
([81BrMH], 100%); HRMS (ESI) C9H5BrN4NaS ([79BrMH])
requires: 278.9335; found 278.9344, ([81BrMH]) requires
280.9314; found 280.9321.
4.3.22. 7-Bromo-5H-[1,2,4]triazino[5,6-b]indole-3-thiol (32)
6-Bromoisatin 28 (1.00 g, 4.45 mmol), thiosemicarbazide
(405 mg, 4.45 mmol) and K2CO3 (920 mg, 6.67 mmol) were sus-
pended in water (50 mL). The reaction mixture was stirred at reﬂux
for 16 h over which time the dark brown suspension became aclear light brown solution. The solution was carefully acidiﬁed by
dropwise addition of acetic acid and resulting precipitate was ﬁl-
tered. The precipitate was recrystallised from DMF to yield the title
compound (32) as a red solid (1.12 g, 90%); mp (Gallenkamp)
>300 C; mmax (solid) 2919 (br), 1589, 1422, 1359, 1161; dH
(500 MHz, DMSO-d6, 363 K) 7.50 (1H, d, J = 7.5 Hz, C(8)H), 7.60
(1H, s, C(6)H), 7.94 (1H, 1H, d, J = 7.5 Hz, C(9)H); dC (125 MHz,
DMSO-d6) 105.5, 120.3, 121.3, 124.8, 134.6, 136.1, 142.4, 150.2,
179.8; m/z (ESI) 279 ([79BrMH], 100%), 281 ([81BrMH],
100%); HRMS (ESI) C9H5BrN4NaS ([79BrMH]) requires:
278.9335; found 278.9343, ([81BrMH]) requires 280.9314;
found 280.9321.4.3.23. 8-Bromo-5H-[1,2,4]triazino[5,6-b]indole-3-thiol (33)
5-Bromoisatin 29 (1.00 g, 4.45 mmol), thiosemicarbazide
(405 mg, 4.45 mmol) and K2CO3 (920 mg, 6.67 mmol) were sus-
pended in water (50 mL). The reaction mixture was stirred at reﬂux
for 16 h over which time the dark brown suspension became a
clear light brown solution. The solution was carefully acidiﬁed by
dropwise addition of acetic acid and resulting precipitate was ﬁl-
tered. The precipitate was recrystallised from DMF to yield the title
compound (33) as a red solid (1.23 g, 97%); mp (Gallenkamp)
>300 C; mmax (solid) 3097, 2858, 1603, 1589, 1446, 1311; dH
(500 MHz, DMSO-d6, 363 K) 1.90 (1H, br s, NH), 7.38 (1H, d,
J = 8.6 Hz, C(6)H), 7.74 (1H, dd, J = 8.6, 1.8 Hz, C(7)H), 8.15, (1H, d,
J = 1.8 Hz, C(9)H); dC (125 MHz, DMSO-d6) 115.6, 115.9, 120.8,
125.0, 134.9, 135.8, 143.5, 150.4, 180.1; m/z (ESI) 279
([79BrMH], 100%), 281 ([81BrMH], 100%); HRMS (ESI) C9H5
BrN4NaS ([79BrMH]) 278.9335; found 278.9343, ([81BrMH])
requires 280.9314; found 280.9320.
4.3.24. 9-Bromo-5H-[1,2,4]triazino[5,6-b]indole-3-thiol (34)
4-Bromoisatin 30 (1.00 g, 4.45 mmol), thiosemicarbazide
(405 mg, 4.45 mmol) and K2CO3 (920 mg, 6.67 mmol) were sus-
pended in water (50 mL). The reaction mixture was stirred at reﬂux
for 16 h over which time the dark brown suspension became a
clear light brown solution. The solution was carefully acidiﬁed by
dropwise addition of acetic acid and resulting precipitate was ﬁl-
tered. The precipitate was recrystallised from DMF to yield the title
compound (34) as a red solid (1.18 g, 95%); mp (Gallenkamp)
>300 C; mmax (solid) 3389 (br), 3297, 1604, 1573, 1140; dH
(500 MHz, DMSO-d6, 363 K) 7.43–7.52 (3H, m, C(6)H, C(7)H), and
C(8)H), 14.68 (1H, br s, NH); dC (125 MHz, DMSO-d6) 113.0,
117.0, 118.3, 127.4, 133.5, 136.1, 145.3, 149.9, 180.0; m/z (ESI)
279 ([79BrMH], 100%), 281 ([81BrMH], 100%); HRMS (ESI)
C9H5BrN4S ([79BrMH]) requires: 278.9335; found 278.9343,
([81BrMH]) requires 280.9314; found 280.9320.
4.3.25. 20-(((6-Bromo-5H-[1,2,4]triazino[5,6-b]indol-3-
yl)thio)methyl)benzonitrile (35)
Following General procedure 1, to 6-bromo-5H-[1,2,4]triazi-
no[5,6-b]indol-3-thiol 31 (100 mg, 0.36 mmol) and Et3N (75 lL,
0.54 mmol) in methanol (5 mL) was added 2-cyanobenzyl bromide
(70 mg, 0.36 mmol) and the resulting mixture stirred at rt for 16 h.
The resulting precipitate was ﬁltered and washed to give the title
compound (35) as a light yellow solid (128 mg, 87%); mp (Gallenk-
amp) 226–228 C; mmax (solid) 3065, 2780, 2228, 1600, 1401, 1436;
HPLC (Method 2) >98%, tR = 11.47 min; dH (500 MHz, DMSO-d6,
363 K) 4.74 (2H, s, S-CH2), 7.34 (1H, app t, J = 7.8 Hz, C(8)H), 7.47
(1H, app t, J = 8.1 Hz, C(40)H), 7.66 (1H, app t, J = 7.8 Hz, C(50)H),
7.84–7.89 (3H, m, C(7)H, C(30)H and C(60)H), 8.29 (1H, d,
J = 7.6 Hz, C(9)H), 12.94 (1H, br s, NH); dC (125 MHz, DMSO-d6)
33.45, 106.0, 112.8, 118.31, 120.6, 121.5, 124.7, 129.1, 131.4,
134.0, 134.2, 134.2, 139.9, 141.9, 142.2, 148.0, 167.4; m/z (ESI)
394 ([79BrMH], 100%), 396 ([81BrMH], 100%); HRMS (ESI+)
254 M. Gianella-Borradori et al. / Bioorg. Med. Chem. 23 (2015) 241–263C17H10BrN5NaS ([79BrM+Na]+) requires 417.9732; found 417.9733,
([81BrM+Na]+) requires 419.9713; found 419.9717.
4.3.26. 2-(((7-Bromo-5H-[1,2,4]triazino[5,6-b]indol-3-
yl)thio)methyl)benzonitrile (36)
Following General procedure 1, to 8-bromo-5H-[1,2,4]triazi-
no[5,6-b]indole-3-thiol 32 (100 mg, 0.36 mmol) and Et3N (75 lL,
0.54 mmol) in methanol (5 mL), 2-cyanobenzyl bromide (70 mg,
0.36 mmol) were stirred overnight at rt for 16 h. The resulting pre-
cipitate was ﬁltered and washed to give the title compound (36) as
a light yellow solid (130 mg, 92%); mp (Gallenkamp) 289–291 C;
mmax (solid) 3076, 3012, 2701, 2228, 1608, 1420; dH (400 MHz,
DMSO-d6) 4.75 (2H, s, CH2), 7.48 (1H, app t, J = 7.9 Hz, C(50)H),
7.60 (1H, dd, J = 8.2, 1.6 Hz, C(8)H), 7.68 (1H, app t, J = 7.9 Hz,
C(40)H), 7.77 (1H, d, J = 1.6 Hz, C(6)H), 7.84 (1H, d, J = 7.9 Hz,
C(30)H), 7.88 (1H, dd, J = 7.9, 1.3 Hz, C(60)H), 8.26 (1H, d,
J = 8.2 Hz, C(9)H), 12.81 (1H, br s, NH); dC (100 MHz, DMSO-d6)
32.5, 112.0, 115.5, 116.9, 117.5, 123.2, 123.7, 125.6, 128.3, 130.4,
133.1, 133.3, 140.9, 141.1, 141.3, 146.9, 166.2; m/z (ESI) 394
([79BrMH], 100%), 396 ([81BrMH], 100%); HRMS (ESI+) C17H10
BrN5NaS ([79BrM+Na]+) requires 417.9732; found 417.9738,
([81BrM+Na]+) requires 419.9712; found 419.9718.
4.3.27. 2-(((8-Bromo-5H-[1,2,4]triazino[5,6-b]indol-3-
yl)thio)methyl)benzonitrile (37)
Following General procedure 1, to 8-bromo-5H-[1,2,4]triazi-
no[5,6-b]indole-3-thiol 33 (100 mg, 0.36 mmol), Et3N (75 lL,
0.54 mmol) in methanol (5 mL) was added 2-cyanobenzyl bromide
(70 mg, 0.36 mmol) and were stirred at rt for 16 h. The resulting
precipitate was washed to give the title compound (37) as a light
yellow solid (110 mg, 78%); mp (Gallenkamp) 286–288 C; mmax
(solid) 3091, 2967, 2796, 2225, 1591; HPLC (Method 2) >96%,
tR = 11.72 min; dH (400 MHz, DMSO-d6) 4.73 (2H, s, CH2), 7.47
(1H, t, J = 7.6 Hz, C(40)H), 7.53 (1H, d, J = 8.6 Hz, C(6)H), 7.66 (1H,
t, J = 7.6 Hz, C(50)H), 7.78–7.88 (3H, m, C(7)H, C(30)H and C(60)H),
8.43 (1H, s, C(9)H), 12.80 (1H, br s, NH); dC (100 MHz, DMSO-d6)
33.4, 112.9, 115.4, 115.7, 118.3, 120.4, 124.7, 129.11, 131.3,
134.0, 134.2, 140.0, 142.0, 147.5, 153.7, 155.0, 167.4; m/z (ESI)
394 ([79BrMH], 100%), 396 ([81BrMH], 100%); HRMS (ESI+)
C17H10BrN5NaS ([79BrM+Na]+) requires 417.9732; found
417.9740, ([81BrM+Na]+) requires 419.9713; found 419.9796.
4.3.28. 20-(((9-Bromo-5H-[1,2,4]triazino[5,6-b]indol-3-
yl)thio)methyl)benzonitrile (38)
Following General procedure 1, 9-bromo-5H-[1,2,4]triazi-
no[5,6-b]indol-3-thiol 34 (100 mg, 0.36 mmol) and Et3N (75 lL,
0.54 mmol) in methanol (5 mL), 2-cyanobenzyl bromide (70 mg,
0.36 mmol) was added at rt and stirred for 16 h. The resulting pre-
cipitate was ﬁltered and washed to give the title compound (38) as
a light yellow solid (91 mg, 64%); mp (Gallenkamp) 283–284 C;
mmax (solid) 3269 (br), 3076, 3039, 2232, 1583, 1304, 1168; HPLC
(Method 2) >99%, tR = 11.42 min; dH (400 MHz, DMSO-d6, 363 K)
4.76 (2H, s, S-CH2), 7.48 (1H, app t, J = 7.8 Hz, C(50)H), 7.55–7.64
(3H, m, C(6)H, C(7)H, C(9)H), 7.67 (1H, app t, J = 7.8 Hz, C(40)H),
7.83 (1H, d, J = 7.8 Hz, C(30)H), 7.88 (1H, dd, J = 7.8, 1.0 Hz,
C(60)H), 12.89 (1H, br s, NH); dC (100 MHz, DMSO-d6) 33.4, 112.8,
112.9, 116.9, 117.9, 118.3, 127.0, 129.1, 131.2, 132.5, 134.0,
134.2, 141.9, 142.5, 147.3, 149.1, 167.0; m/z (ESI) 394
([79BrMH], 100%), 396 ([81BrMH], 100%); HRMS (ESI+) C17H10
BrN5NaS ([79BrM+Na]+) requires 417.9732; found 417.9740,
([81BrM+Na]+) requires 419.9713; found 419.9783.
4.3.29. 9-Bromo-3-((20-nitrobenzyl)thio)-5H-[1,2,4]triazino[5,6-
b]indole (39)
Following General procedure 1, 9-bromo-5H-[1,2,4]triazi-
no[5,6-b]indol-3-thiol 34 (100 mg, 0.36 mmol) and Et3N (75 lL,0.54 mmol) in methanol (5 mL), 2-nitrobenzyl bromide (70 mg,
0.36 mmol) was added at rt and stirred for 16 h. The resulting pre-
cipitate was ﬁltered and washed to give the title compound (39) as
a light yellow solid (98 mg, 66%); mp (Gallenkamp) 285–286 C;
mmax (solid) 3111, 2877, 2832, 1606, 1521, 1338; C16H10BrN5O2S
requires C, 46.17; H, 2.42; N, 16.82; found C, 46.12; H, 2.29; N,
16.63; dH (400 MHz, DMSO-d6, 363 K) 4.90 (2H, s, S-CH2), 7.42–
7.62 (4H, m, C(6)H, C(7)H, C(8)H and C(40)H), 7.69 (1H, app t,
J = 7.8 Hz, C(50)H), 7.93 (1H, dd, J = 7.8, 1.3 Hz, C(60)H), 8.06 (1H,
dd, J = 7.8, 1.3 Hz, C(30)H); dC (100 MHz, DMSO-d6) 32.0, 112.6,
116.9, 118.1, 125.8, 126.7, 128.5, 129.7, 132.3, 133.3, 134.6,
141.2, 142.4, 147.2, 149.2, 167.1; m/z (ESI) 414 ([79BrMH],
100%), 416 ([81BrMH], 100%); HRMS (ESI) C16H10BrN5NaO2S
([79BrMH]) requires 413.9666; found 413.9680, ([81BrMH])
requires 415.9646; found 415.9658.
4.3.30. 4-Bromo-1-(4-methoxybenzyl)indoline-2,3-dione (40)72
4-Bromoisatin 30 (2.00 g, 8.85 mmol) was added to a suspen-
sion of NaH (60% dispersion in mineral oil, 550 mg, 8.85 mmol)
in DMF (20 mL) at 0 C. The resulting purple solution was stirred
at 0 C for 10 min before dropwise addition of p-methoxybenzyl
chloride (1.12 mL, 8.23 mmol). The reaction mixture was stirred
for 30 min at 0 C, heated to 40 C for 3 h, cooled down and
quenched with water. The solution was extracted with EtOAc
(3  30 mL), the combined organic phases were washed with brine,
dried (Na2SO4), ﬁltered and concentrated in vacuo to give the crude
compound as an orange solid. Recrystallisation in EtOAc/petrol
afforded the isatin 40 as an orange powder (2.10 g, 6.09); dH
(CDCl3, 400 MHz) 3.80 (3H, s, O-CH3), 4.88 (2H,s, N-CH2), 6.76
(1H, d, J = 7.8 Hz, C(7)H), 6.88 (d, J = 8.3 Hz, 2H, phenyl ArH), 7.22
(d, J = 8.1 Hz, 1H, C(5)H), 7.26 (d, J = 8.3 Hz, 2H, phenyl ArH), 7.30
(t, J = 8.1 Hz, 1H, C(6)H); LRMS m/z (ESI+) 347 [M+H]+, 715
[2M+Na]+.
4.3.31. 4-(20-Methylphenyl)indoline-2,3-dione (41)
To a solution of 4-bromoisatin 30 (100 mg, 0.44 mmol) in
degassed THF/water (3:1, 2.5 mL) was added potassium 2-methyl-
phenyltriﬂuoroborate (114 mg, 0.62 mmol) and K3PO4 (338 mg,
1.59 mmol) followed by Pd(PPh3)2Cl2 (31 mg, 0.04 mmol). The
reaction vessel was sealed and heated by microwave irradiation
for 4 h at 130 C. The reaction mixture was cooled to rt, diluted
with EtOAc (5 mL) and ﬁltered through Celite. The organic
solution was washed with brine (5 mL) and the resulting aqueous
layer was further extracted with EtOAc (2). The combined organic
layers were dried (MgSO4), ﬁltered and concentrated in vacuo to
give the crude product. The product was puriﬁed via ﬂash column
chromatography (eluent 40–60 C, petrol/EtOAc, 4:1) to afford
the title compound (41) as an orange solid (40 mg, 42%); mp
161–162 C; mmax (solid) 3249, 3017, 2926, 1727, 1603, 1480; dH
(500 MHz, DMSO-d6) 2.15 (3H, s, CH3), 6.93 (2H, m, C(5)H and
C(7)H), 7.14 (1H, d, J = 7.6 Hz, C(60)H), 7.20–7.26 (1H, m, C(40)H),
7.30 (1H, d, J = 7.3 Hz, C(30)H), 7.32–7.37 (1H, m, C(50)H), 7.56
(1H, app t, J = 7.9 Hz C(6)H), 8.84 (1H, br s, NH); dC (125 MHz,
DMSO-d6) 19.7, 111.2, 115.7, 125.6, 126.3, 128.6, 128.8, 130.1,
135.7, 136.4, 137.9, 142.8, 149.3, 159.2, 182.0; m/z (ESI) 236
([MH], 60%); HRMS (ESI) C15H10NO2 ([MH]) requires
236.0717; found 236.0719.
4.3.32. 4-(40-Methylphenyl)indoline-2,3-dione (42)
To a solution of 4-bromoisatin 30 (100 mg, 0.44 mmol) in
degassed THF/H2O (3:1, 3 mL) was added potassium 4-methyphe-
nyltriﬂuoroborate (123 mg, 0.62 mmol) and K3PO4 (338 mg,
1.59 mmol) followed by Pd(PPh3)2Cl2 (31 mg, 0.04 mmol). The
reaction vessel was sealed and heated by microwave irradiation
for 4 h at 130 C. The reaction mixture was cooled to rt, diluted
with EtOAc (5 mL) and ﬁltered through Celite. The organic
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layer was further extracted with EtOAc (2). The combined organic
layers were dried (MgSO4), ﬁltered and concentrated in vacuo to
give the crude product. The product was puriﬁed via ﬂash column
chromatography (eluent 30–40 C petrol/acetone, 4:1) to afford the
title compound (42) as an orange solid (72 mg, 68%); mp 178–
179 C; mmax (solid) 3274, 3051, 2906, 1741, 1609, 1486; dH
(400 MHz, CDCl3) 2.43 (3H, s, CH3), 6.88 (1H, d, J = 8.0 Hz, C(7)H),
7.08 (1H, d, J = 8.0 Hz, C(5)H), 7.28 (2H, d, J = 8.5 Hz, C(30)H and
C(50)H), 7.45 (2H, d, J = 8.5 Hz, C(60)H and C(20)H), 7.55 (1H, app t,
J = 8.0 Hz, C(6)H), 8.70 (1H, br s, NH); dC (125 MHz, CDCl3) 21.4,
110.8, 114.4, 125.9, 128.8, 129.0, 133.1, 138.0, 139.4, 143.8,
154.2, 159.2, 178.3; m/z (ESI) 236 ([MH], 100%); HRMS (ESI)
C15H10NO2S ([MH]) requires 236.0717; found 236.0716.
4.3.33. 4-(30-Thienyl)indoline-2,3-dione (43)
To a solution of 4-bromoisatin 30 (200 mg, 0.88 mmol) in THF/
water (3:1, 3 mL) was added potassium 3-thienyltriﬂuoroborate
(235 mg, 1.24 mmol) and K3PO4 (675 mg, 3.19 mmol) followed by
Pd(PPh3)2Cl2 (62 mg, 0.09 mmol). The reaction vessel was sealed
and heated by microwave irradiation for 4 h at 130 C. The reaction
mixture was cooled to rt, diluted with EtOAc (10 mL) and ﬁltered
through Celite. The organic solution was washed with brine
(10 mL) and the resulting aqueous layer was further extracted with
EtOAc (2). The combined organic layers were dried (MgSO4), ﬁl-
tered and concentrated in vacuo to give the crude product. The
product was puriﬁed via ﬂash column chromatography (eluent
30–40 C petrol/acetone, 4:1) to afford the title compound (43)
as an orange solid (120 mg, 59%); mp 213–216 C; mmax (solid)
3098, 2927, 1727, 1584; dH (500 MHz, DMSO-d6) 6.85 (1H, dd,
J = 7.9, 0.6 Hz, C(7)H), 7.20 (1H, dd, J = 7.9, 0.6 Hz, C(5)H), 7.50
(1H, dd, J = 4.9, 1.3 Hz, C(40)H), 7.58 (1H, app t, J = 7.9 Hz, C(6)H),
7.62 (1H, dd, J = 4.9, 2.9 Hz, C(50)H), 8.07 (1H, dd, J = 2.9, 1.3 Hz,
C(20)H), 11.13 (1H, br s, NH); dC (125 MHz, DMSO-d6) 110.8,
113.9, 123.8, 125.6, 126.3, 128.4, 135.8, 137.2, 138.0, 151.6,
158.9, 183.0; m/z (ESI) 228 ([MH], 100%); HRMS (ESI) C12H6
N4O2S ([MH]) requires 228.0125; found 228.0127.
4.3.34. 4-Cyclopropyl-1-(4-methoxybenzyl)indoline-2,3-dione
(44)
Bromoisatin 30 (683 mg, 1.98 mmol), potassium cycloproplytri-
ﬂuoroborate (410 mg, 2.77 mmol), K3PO4 (1.51 g, 7.13 mmol) were
added sequentially to a microwave vial before addition of degassed
THF/H2O (3:1, 9 mL). The reaction mixture was further degassed
before addition of Pd(dppf)Cl2 (141 mg, 0.193 mmol). The reaction
vessel was sealed and heated by microwave irradiation for 4 h at
130 C. The reaction mixture was cooled to room temperature, ﬁl-
tered through Celite, using EtOAc as an eluent. The solution was
washed with brine (20 mL), dried (Na2SO4), ﬁltered and concen-
trated in vacuo to give the crude compoundas a black greenoil. Puri-
ﬁcation on silica gel (CH2Cl2) afforded the title compound (44) as an
orange solid (586 mg, 96%).mp 175–178 C; mmax (solid) 1727, 1608,
1590, 1514, 1454, 1247, 1182, 1030; dH (500 MHz, acetone-d6) 0.85
(2H, ddd, J = 9.0, 6.6, 4.4 Hz, C(20)H or C(30)H), 1.14 (2H, ddd, J = 8.5,
6.8, 4.4 Hz, C(20)H or C(30)H), 2.96 (1H, app tt, J = 8.5, 5.0 Hz, C(10)H),
3.76 (3H, s,O-CH3), 4.88 (2H, s,N-CH2), 6.55 (1H, d, J = 8.0 Hz, C(7)H),
6.74 (1H, dd, J = 7.9, 0.8 Hz, C(5)H), 6.90 (2H, d, J = 8.7 Hz, ArH), 7.38
(3H, m, ArH and C(6)H); dC (125 MHz, acetone-d6) 11.4, 43.6, 55.6,
108.4, 115.0, 116.7, 118.4, 128.6, 129.8, 138.7, 149.0, 151.8, 159.0,
160.4, 185.0; LRMS m/z (ESI+) 308 ([M+H]+); HRMS (ESI+) C19H17
NNaO3+ ([M+Na]+) requires 330.1110; found 330.1110.
4.3.35. 9-(20-Methylphenyl-5H-[1,2,4]triazino[5,6-b]indole-3-
thiol (45)
4-(20-Methylphenyl)indoline-2,3-dione 41 (70 mg, 0.31 mmol),
thiosemicarbazide (29 mg, 0.31 mmol) and K2CO3 (65 mg,0.47 mmol) were suspended in water (7 mL) and heated at reﬂux
overnight. The solution was acidiﬁed and the resulting precipitate
was ﬁltered to yield the crude product which was recrystallised
from DMF to afford the title compound (45) as a yellow solid
(59 mg, 67%); mp 297–299 C; mmax (solid) 3204, 3045, 2922,
2361, 1473; dH (500 MHz, DMSO-d6) 2.26 (3H, s, CH3), 7.12 (1H,
dd, J = 7.8, 0.6 Hz, C(6)H), 7.25–7.28 (2H, m, C(20)H and C(30)H or
C(40)H), 7.31–7.34 (2H, m, C(30) or C(40)H and C(50)H), 7.45 (1H,
dd, J = 7.8, 0.6 Hz, C(8)H), 7.68 (1H, app t, J = 7.8 Hz, C(7)H), 12.52
(1H, br s, NH), 14.27 (1H, s, SH); dC (125 MHz, DMSO-d6) 19.5,
111.7, 115.9, 124.5, 125.7, 128.1, 129.1, 130.0, 131.6, 135.4,
135.7, 137.9, 138.4, 143.1, 149.0, 178.7; m/z (ESI) 291 ([MH],
100%); HRMS (ESI) C16H11N4S ([MH]) requires 291.0710;
found 291.0715.
4.3.36. 9-(40-Methylphenyl)-5H-[1,2,4,]triazino[5,6-b]indole-3-
thiol (46)
4-(4-Methylphenylindoline-2,3-dione 42 (38 mg, 0.16 mmol),
thiosemicarbazide (15 mg, 0.16 mmol) and K2CO3 (33 mg,
0.24 mmol) were suspended in water (4 mL) and stirred at reﬂux
overnight. The solution was acidiﬁed and resulting precipitate
was ﬁltered to yield the crude product which was recrystallised
from DMF to afford the title compound (46) as a yellow solid
(14 mg, 30%); mp >300 C; mmax (solid) 3224, 3049, 2890, 2571,
1488; dH (500 MHz, DMSO-d6) 2.39 (3H, s, CH3) 7.25 (1H, d,
J = 7.9 Hz, C(6)H), 7.29 (2H, d, J = 7.9 Hz, C(30)H and C(50)H), 7.41
(1H, d, J = 8.2 Hz, C(8)H), 7.58 (2H, d, J = 8.2 Hz, C(20)H and
C(60)H), 7.67 (1H, app t, J = 7.9 Hz, C(7)H), 12.50 (1H, s, NH),
14.31 (1H, s, SH); dC (125 MHz, DMSO-d6) 20.9, 111.5, 114.8,
124.2, 128.7, 128.8, 131.8, 135.2, 135.9, 137.6, 138.8, 143.7,
149.0, 178.6; m/z (LRMS, ESI) 291 ([MH], 60%); HRMS (ESI)
C16H11N4S ([MH]) requires 291.0710; found 291.0716.
4.3.37. 9-(30-Thienyl)-5H-[1,2,4]triazino[5,6-b]indol-3-thiol (47)
4-(30-Thienyl)indoline-2,3-dione 43 (137 mg, 0.60 mmol), thio-
semicarbazide (54 mg, 0.60 mmol) and K2CO3 (124 mg, 0.90 mmol)
were suspended in water (5 mL) and stirred at reﬂux overnight.
The solution was acidiﬁed by dropwise addition of acetic acid
and the resulting precipitate was ﬁltered to yield the crude product
which was recrystallised from DMF to afford the title compound
(47) as an orange solid (148 mg, 87%); mp >300 C; mmax (solid)
3214, 3016, 2926, 1593; dH (500 MHz, DMSO-d6) 7.40 (1H, dd,
J = 7.9, 0.6 Hz, C(6)H), 7.46 (1H, dd, J = 7.9, 0.6 Hz, C(8)H), 7.63
(1H, app td, J = 7.9, 1.2 Hz, C(7)H), 7.65–7.69 (2H, m, C(40)H and
C(50)H), 8.12 (1H, dd, J = 3.2, 1.3 Hz, C(20)H), 12.54 (1H, br s, NH),
14.45 (1H, br s, SH); dC (125 MHz, DMSO-d6) 111.6 (C6), 114.4
(C9a), 123.8 (C8), 125.3 (C20), 125.8 (C50), 128.4, 131.8, 133.2,
135.8, 138.6, 143.8, 148.9, 178.5; m/z (ESI) 283 ([MH], 100%)
HRMS (ESI) C13H7N4S2 ([MH]) requires 283.0118; found
283.0115.
4.3.38. 4-Cyclopropylindoline-2,3-dione (48)
4-Cyclopropyl-1-(4-methoxybenzyl)indoline-2,3-dione 44
(330 mg, 1.08 mmol) was dissolved in TFA (3 mL) and the resulting
solution heated to 90 C in a sealed tube for overnight. After being
cooled, the reaction was treated carefully with NaHCO3 (satd aq)
and extracted with EtOAc (3  30 mL). The combined organic
phase was dried (Na2SO4), ﬁltered and concentrated in vacuo to
give the crude compound as a dark solid. Puriﬁcation on silica
gel (acetone/CH2Cl2, 1:50) afforded the title compound 48 as a
orange solid (136 mg, 67%) and recovered starting material 44
(75 mg, 21%); mp 143–145 C; mmax (solid) 3268, 2360, 1755,
1724, 1619, 1591, 1497; dH (500 MHz, acetone-d6) 0.86 (2H, ddd,
J = 6.4, 5.0, 4.4 Hz, C(20)H or C(30)H), 1.13 (2H, ddd, J = 8.5, 6.6,
4.4 Hz, C(20)H or C(30)H), 2.97 (1H, app tt, J = 8.5, 5.0 Hz, C(10)H),
6.54 (1H, d, J = 8.1 Hz, C(7)H), 6.73 (1H, dd, J = 7.7, 0.8 Hz, C(5)H),
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117.2, 118.0, 139.1, 149.1, 151.4, 159.8, 185.5; LRMSm/z (ESI+) 188
([M+H]+); HRMS (ESI+) C11H9NNaO2+ ([M+Na]+) requires 210.0525;
found 210.0524.
4.3.39. 9-Cyclopropyl-5H-[1,2,4]triazino[5,6-b]indole-3-thiol
(49)
To a stirred suspension of 4-cyclopropylindoline-2,3-dione 48
(135 mg, 0.722 mmol) and K2CO3 (150 mg, 1.08 mmol) in water
(10 mL), was added thiosemicarbazide (72 mg, 0.794 mmol). The
mixture was heated under rapid reﬂux for 16 h. Upon cooling,
the solution was acidiﬁed (pH 6) with glacial acetic acid to
afford a precipitate, which was ﬁltered and washed with water,
followed by cold acetone and Et2O. The resulting solid was tritu-
rated with DMF, ﬁltered and dried to yield the title compound
(49) as a bright yellow solid (124 mg, 71%); mp >300 C; mmax
(solid) 3012, 2882, 1611, 1584, 1306, 1157; dH (500 MHz,
DMSO-d6) 0.90 (2H, ddd, J = 6.4, 4.9, 4.4 Hz, C(20)H or C(30)H),
1.16 (2H, ddd, J = 8.3, 6.6, 4.4 Hz, C(20)H or C(30)H), 2.77 (1H,
app tt, J = 8.3, 5.0 Hz, C(10)H), 6.77 (1H, d, J = 8.0 Hz, C(7)H),
7.18 (1H, dd, J = 7.9, 0.8 Hz, C(5)H), 7.48 (1H, t, J = 8.0 Hz,
C(6)H), 12.45 (1H, br s, NH), 14.57 (1H, br s, SH); dC (125 MHz,
DMSO-d6) 10.4, 12.4, 109.5, 116.2, 131.9, 136.8, 142.6, 142.9,
149.1, 178.5; LRMS m/z (ESI+) 243 ([M+H]+); HRMS (ESI+) C12H10
N4SNa+ ([M+Na]+) requires 265.0518; found 265.0523.
4.3.40. 20-(((9-(20-Methylphenyl-5H-[1,2,4]triazino[5,6-b]indol-
3-yl)thio)methyl)benzonitrile (50)
Following General procedure 1, 9-(40-methylphenyl)-5H-
[1,2,4]triazino[5,6-b]indole-3-thiol 45 (40 mg, 0.14 mmol), Et3N
(30 lL, 0.22 mmol), methanol (2.5 mL) and 2-(bromomethyl)ben-
zonitrile (28 mg, 0.14 mmol) gave the title compound (50) as a pale
yellow solid (36 mg, 63%); mp 217–219 C; mmax (solid) 3203, 3121,
2936, 2225, 1581; dH (500 MHz, DMSO-d6) 2.06 (3H, s, C(20)CH3),
4.71 (2H, s, S-CH2), 7.22 (1H, dd, J = 7.9, 0.6 Hz, C(6)H), 7.25–7.33
(2H, m, C(20)H and C(30)H or C(40)H), 7.33–7.39 (2H, m, C(30)H
and C(30)H or C(40)H), 7.48 (1H, app td, J = 7.6, 0.9 Hz, C(500)H),
7.61 (1H, dd, J = 7.9, 0.6 Hz, C(8)H), 7.66 (1H, app td, J = 7.6,
1.3 Hz, C(400)H), 7.75 (1H, app t, J = 7.9 Hz, C(7)H), 7.78 (1H, d,
J = 7.6 Hz, C(300)H), 7.86 (1H, dd, J = 7.6, 1.3 Hz, C(600)H), 12.81 (1H,
s, NH); dC (125 MHz, DMSO-d6) 19.6, 32.4, 111.5, 111.9, 115.8,
117.4, 123.9, 125.5, 127.8, 128.3, 129.3, 129.8, 130.4, 130.7,
133.2, 133.4, 135.7, 137.8, 139.0, 140.4, 141.0, 141.6, 146.3,
165.4; m/z (ESI+) 408 ([M+H]+, 20%); HRMS (ESI) C24H16N5S
([MH]) requires 406.1132; found 406.1125.4.3.41. 2-(((9-(40-Methylphenyl)-5H-[1,2,4]triazino[5,6-b]indol-
3-yl)thio)methyl)benzonitrile (51)
Following General procedure 1, 9-(40-methylphenyl)-5H-
[1,2,4]triazino[5,6-b]indole-3-thiol 46 (14 mg, 0.05 mmol), Et3N
(10 lL, 0.07 mmol), 2-(bromomethyl)benzonitrile (10 mg,
0.05 mmol) in methanol (1.5 mL) gave the title compound (51) as
a pale yellow solid (12 mg, 56%); mp (Gallenkamp) 239–241 C;
mmax (solid) 3335, 3035, 2916, 2224, 1611; dH (500 MHz, DMSO-
d6) 2.42 (3H, s, CH3), 4.74 (2H, s, S-CH2), 7.33 (2H, d, J = 8.1 Hz,
C(30)H and C(50)H), 7.36 (1H, dd, J = 7.6, 0.8 Hz, C(6)H), 7.49 (1H,
app td, J = 7.9, 0.9 Hz, C(500)H), 7.57 (1H, dd, J = 7.6, 0.8 Hz, C(8)H),
7.67 (1H, app td, J 7.9, 1.3 Hz, C(400)H), 7.71 (2H, d, J = 8.1 Hz,
C(20)H and C(60)H), 7.74 (1H, app t, J = 7.6 Hz, C(7)H), 7.80 (1H, d,
J = 7.9 Hz, C(600)H), 7.88 (1H, dd, J = 7.9, 0.9 Hz, C(300)H), 12.79 (1H,
s, NH); dC (125 MHz, DMSO-d6) 20.9, 32.5, 111.3, 111.9, 114.6,
117.4, 123.7, 128.3, 128.7, 129.1, 130.4, 130.9, 133.2, 133.4,
135.6, 137.5, 138.8, 141.0, 141.1, 142.0, 146.3, 165.3; m/z (ESI)
406 ([MH], 100%); HRMS (ESI) C24H16N5S ([MH]) requires
406.1123; found 406.1125.4.3.42. 200-(((9-(30-Thienyl)-5H-[1,2,4]triazino[5,6-b]indol-3-
yl)thio)methyl)benzonitrile (52)
Following General procedure 1, 9-(30-thienyl)-5H-[1,2,4]triazi-
no[5,6-b]indole-3-thiol 47 (20 mg, 0.07 mmol), Et3N (15 lL,
0.11 mmol), methanol (5 mL) and 2-(bromomethyl)benzonitrile
(14 mg, 0.07 mmol) gave the title compound (52) as a yellow solid
(16 mg, 57%); mp (Gallenkamp) 274–276 C; mmax (solid) 3217,
3095, 2863, 2236, 1579; dH (500 MHz, DMSO-d6) 4.76 (2H, s,
S-CH2), 7.39 (1H, d, J = 7.9 Hz, C(6)H), 7.49 (1H, app t, J = 7.6 Hz,
C(500)H), 7.55 (1H, d, J = 7.9 Hz, C(8)H), 7.62 (1H, t, J = 7.6 Hz,
C(400)H), 7.64–7.77 (2H, m, C(7)H and C(40)H), 7.77–7.86 (2H, m,
C(300)H and C(600)H), 8.12 (1H, d, J = 2.9 Hz, C(50)H), 8.46 (1H, d,
J = 2.9 Hz, C(20)H), 12.85 (1H, br s, NH); dC (125 MHz, DMSO-d6)
31.6, 111.0, 111.6, 117.0, 117.4, 124.8, 125.7, 125.9, 128.6, 129.8,
130.8, 132.2, 133.7, 133.2, 133.5, 135.0, 139.7, 140.9, 141.2,
143.9, 163.6; m/z (ESI) 398 ([MH], 50%); HRMS (ESI) C21H12
N5S2 ([MH]) requires 398.0540; found 398.0533.
4.3.43. 2-(((9-Cyclopropyl-5H-[1,2,4]triazino[5,6-b]indol-3-
yl)thio)methyl)benzonitrile (53)
Following General procedure 1, 9-cyclopropyl-5H-[1,2,4]triazi-
no[5,6-b]indole-3-thiol 49 (40 mg, 0.165 mmol) and Et3N (35 lL,
0.248 mmol) in methanol (5 mL), 2-cyanobenzyl bromide (32 mg,
0.165 mmol) were added at rt and stirred for 16 h. The resulting
precipitate was ﬁltered and washed with EtOH, Et2O and petrol
to give the title compound (53) as a light green solid (57 mg,
97%); mp (Gallenkamp) 227–229 C, mmax (solid) 3067, 1584,
1517, 1447, 1328, 1175; dH (500 MHz, DMSO-d6) 0.94 (2H, m,
C(20)H or C(30)H), 1.22 (2H, m, C(20)H or C(30)H), 3.35 (1H, m,
C(10)H), 4.75 (2H, s, S-CH2), 6.87 (1H, d, J = 7.7 Hz, C(7)H), 7.32
(1H, d, J = 7.9 Hz, C(5)H), 7.48 (1H, t, J = 7.6 Hz, C(500)H), 7.55 (1H,
t, J = 7.9 Hz, C(6)H), 7.67 (1H, t, J = 7.6 Hz, C(400)H), 7.83 (1H, d,
J = 7.9 Hz, C(300)H), 7.87 (1H, J = 7.6 Hz, C(600)H), 12.84 (1H, br s,
NH); dC (125 MHz, DMSO-d6) 10.5, 12.6, 32.5, 109.1, 111.9, 115.9,
116.2, 117.5, 128.2, 130.3, 131.0, 133.2, 133.4, 140.3, 141.3,
142.7, 143.0, 146.5, 164.9; LRMS m/z (ESI+) 358 ([M+H]+); HRMS
(ESI+) C20H15N5SNa+ ([M+Na]+) requires 380.940; found 380.939.
4.3.44. 2-(((5-Methyl-5H-[1,2,4]triazino[5,6-b]indol-3-
yl)thio)methyl)benzonitrile (54)
Following General procedure 2, to 5H-[1,2,4]triazino[5,6-
b]indole-3-thiol 7 (100 mg, 0.32 mmol) in THF (5 mL) was added
NaH (60% dispersion in mineral oil, 13.8 mg, 0.35 mmol) followed
by methyl iodide (29 lL, 0.47 mmol) at 0 C and the resulting mix-
ture stirred at rt for 16 h. The reaction mixture was quenched with
water (30 mL) and CH2Cl2 (30 mL) added. The organic layer was
separated and washed with brine (30 mL), dried (MgSO4), ﬁltered
and concentrated in vacuo. The resulting solid was washed with
methanol to yield the title compound (54) as a yellow solid
(72 mg, 69%); mp (Gallenkamp) 219–221 C; mmax (solid) 3392,
2221, 1573, 1467, 1358, 1325; HPLC (Method 1) >99%,
rt = 10.93 min; dH (400 MHz, pyr-d5, 363 K) 3.68 (2H, s, S-CH2),
4.99 (3H, s, N-CH3), 7.30 (1H, t, J = 7.8 Hz, C(50)H), 7.42 (1H, t,
J = 7.8 Hz, C(8)H), 7.46 (1H, d, J = 7.8 Hz, C(6)H), 7.52 (1H, t,
J = 7.8 Hz, C(40)H), 7.66 (1H, t, J = 7.8 Hz, C(7)H), 7.74 (1H, d,
J = 7.8 Hz, C(30)H), 7.95 (1H, d, J = 7.8 Hz, C(60)H), 8.43 (1H, d,
J = 7.8 Hz, C(9)H); dC (100 MHz, pyr-d5) 28.7, 35.1, 112.4, 118.2,
118.6, 120.2, 123.6, 124.8, 129.0, 129.9, 132.4, 132.7, 134.6,
134.9, 143.6, 144.1, 144.9, 167.2; m/z (ESI+) 354 ([M+Na]+, 100%);
HRMS (ESI+) C18H13N5NaS ([M+Na]+) requires 354.0784; found
354.0786.
4.3.45. 20-(((5-Ethyl-5H-[1,2,4]triazino[5,6-b]indol-3-
yl)thio)methyl)benzonitrile (55)
Following General procedure 2, 20(((5H-[1,2,4]triazino[5,6-
b]indol-3-yl)thio)methyl)benzonitrile 7 (100 mg, 0.32 mmol) was
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mineral oil, 13.8 mg, 0.34 mmol) was added to the cooled solution
and stirred at 0 C for 10 min. Ethyl iodide (38 lL, 0.47 mmol) was
added and reaction mixture was allowed to warm to rt and stirred
for 16 h. The reaction mixture was quenched by dropwise addition
of water until a precipitate was formed, this was collected by ﬁltra-
tion and dried to yield the title compound (55) as a white powder
(85 mg, 78%); mp (EZ Melt) 187–189 C; mmax (solid) 2923, 2853,
2225, 1570, 1335, 1169; HPLC (Method 2) >97%, tR = 11.31 min;
dH (500 MHz, DMSO-d6, 363 K) 1.34 (3H, t, J = 7.3 Hz, CH3), 4.45
(2H, q, J = 7.3 Hz, N-CH2), 4.77 (2H, s, S-CH2), 7.45–7.48 (1H, m,
C(8)H), 7.49 (1H, app t, J = 7.6 Hz, C(50)H), 7.67 (1H, app td,
J = 7.6, 1.3 Hz, C(40)H), 7.78 (1H, app t, J = 7.6 Hz, C(7)H), 7.82–
7.88 (3H, m, C(6)H, C(30)H and C(60)H), 8.34 (1H, d, J = 7.6 Hz,
C(9)H); dC (125 MHz, DMSO-d6) 13.4, 32.4, 36.0, 111.2, 112.0,
117.4, 117.6, 121.7, 122.9, 128.1, 130.2, 131.1, 133.0, 133.3,
140.5, 141.1, 141.6, 145.5, 165.9; m/z (ESI+) 368 ([M+Na]+, 100%);
HRMS (ESI+) C19H15N5NaS ([M+Na]+) requires 368.0940; found
368.0936.
4.3.46. 2-(((5-Butyl-5H-[1,2,4]triazino[5,6-b]indol-3-
yl)thio)methyl)benzonitrile (56)
Following General procedure 2, 20(((5H-[1,2,4]triazino[5,6-
b]indol-3-yl)thio)methyl)benzonitrile 7 (100 mg, 0.32 mmol), was
added to DMF (5 mL) and cooled to 0 C. To the cooled solution
was added NaH (60% dispersion in mineral oil, 13.8 mg,
0.35 mmol) and stirred at 0 C for 10 min. Iodobutane (54 lL,
0.47 mmol) was added and reaction mixture was stirred for 16 h
at rt, quenched and the resulting precipitate was ﬁltered and dried
to yield the title compound (56) as a white powder (79 mg, 68%);
mp (EZ Melt) 159–161 C; mmax (solid) 2954, 2925, 2221, 1561,
1466, 1171; HPLC (Method 2) >95%, tR = 11.97 min; dH (500 MHz,
DMSO-d6, 363 K), 0.86 (3H, t, J = 7.6 Hz, CH3), 1.22–1.30 (2H, m,
C(300)H2), 1.70–1.76 (2H, m, C(200)H2), 4.38 (2H, t, J = 7.6 Hz,
N-CH2), 4.76 (2H, s, S-CH2), 7.47 (1H, app t, J = 7.9 Hz, C(8)H),
7.48 (1H, app t, J = 7.6 Hz, C(50)H), 7.66 (1H, app t, J = 7.6 Hz,
C(40)H), 7.75 (1H, app t, J = 7.9 Hz, C(7)H), 7.81 (1H, d, J = 7.9 Hz,
C(6)H), 7.84 (1H, d, J = 7.6 Hz, C(30)H), 7.87 (1H, dd, J = 7.6, 1.3 Hz,
C(60), 8.33 (1H, d, J = 7.9 Hz, C(9)H); dC (125 MHz, DMSO-d6) 13.6,
19.5, 29.9, 32.4, 40.8, 111.4, 111.9, 117.3, 117.6, 121.6, 122.9,
128.1, 130.0, 131.0, 133.0, 133.3, 140.8, 140.9, 141.5, 145.9,
165.9; m/z (ESI+) 396 ([M+Na]+, 100%); HRMS (ESI+) C21H19N5NaS
([M+Na]+) requires 396.1253; found 396.1247.
4.3.47. 20-((5-(Cyclopropylmethyl)-5H-[1,2,4,]triazino[5,6-
b]indol-3-ylthio)methyl)benzonitrile (57)
Following General procedure 2, 20-(((5H-[1,2,4]triazino[5,6-
b]indol-3-yl)thio)methyl)benzonitrile 7 (100 mg, 0.32 mmol) was
added to DMF (5 mL), cooled to 0 C followed by the addition of
NaH (60% dispersion in mineral oil, 13.8 mg, 0.35 mmol) and stir-
red at 0 C for 10 min. Bromomethylcyclopropane (31 lL,
0.32 mmol) was added and the resulting mixture stirred at rt for
16 h. The reaction mixture was quenched with water and resulting
precipitate was ﬁltered and washed with methanol to yield the
title compound (57) as a pale yellow solid (62 mg, 52%); mp
(Gallenkamp) 149–150 C; mmax (solid) 3030, 2923, 2251, 1740;
HPLC (Method 2) >99%, tR = 1.66 min; dH (500 MHz, DMSO-d6,
363 K) 0.37–0.50 (4H, m, C(200)H2 and C(300)H2), 1.19–1.33 (1H, m,
C(100)H), 4.32 (1H, d, J = 6.9 Hz, N-CH2), 4.73 (2H, s, S-CH2), 7.48
(2H, m, C(8)H and C(40)H), 7.67 (1H, app t, J = 7.8 Hz, C(7)H), 7.77
(1H, app t, J = 7.6 Hz, C(50)H), 7.8 (1H, d, J = 7.8 Hz, C(6)H), 7.81–
7.99 (2H, m, C(30)H and C(60)H), 8.34 (1H, d, J = 7.8 Hz, C(9)H); dC
(125 MHz, DMSO-d6) 3.8, 10.2, 32.4, 45.2, 111.6, 111.9, 117.3,
117.6, 121.6, 122.9, 128.1, 130.0, 131.0, 133.0, 133.4, 140.9,
141.0, 141.5, 145.8, 166.0; m/z (ESI+) 394 ([M+Na]+, 100%); HRMS
(ESI+) C20H20N5NaS ([M+Na]+) requires 394.1094; found 394.1095.4.3.48. 20-(((5-(Cyclohexylmethyl)-5H-[1,2,4]triazino[5,6-
b]indol-3-yl)thio)methyl)benzonitrile (58)
Following General procedure 2, 20(((5H-[1,2,4]triazino[5,6-
b]indol-3-yl)thio)methyl)benzonitrile 7 (100 mg, 0.32 mmol) was
added to DMF (5 mL), cooled to 0 C followed by the addition of
NaH (60% dispersion in mineral oil, 13.8 mg, 0.34 mmol) and stir-
red at 0 C for 10 min. Bromomethyl cyclohexane (44 lL,
0.32 mmol) was added, stirred for 16 h and quenched with water.
The resulting precipitate was ﬁltered and dried to yield the title
compound (58) as a white solid (25 mg, 19%); mp (EZ Melt) 201–
203 C; mmax (solid) 2926, 2850, 2219, 1571, 1170; HPLC (Method
2) >99%, tR = 12.40 min; dH (500 MHz, DMSO-d6, 363 K) 0.97–1.12
(6H, m, 6 CH), 1.45–1.50 (2H, m, 2 CH), 1.56–1.63 (4H, m, 4
CH), 1.85–1.92 (1H, m, C(100)H), 4.21 (1H, d, J = 7.3 Hz, N-CH2),
4.77 (2H, s, S-CH2), 7.46–7.52 (2H, m, C(50)H and C(8)H), 7.68 (1H
app td, J = 7.6, 1.3 Hz, C(40)H), 7.76 (1H, app t, J = 7.6 Hz, C(7)H),
7.81–7.87 (2H, m, C(30)H and C(6)H), 7.90 (1H, dd, J = 7.6, 1.0 Hz,
C(60)H), 8.35 (1H, d, J = 7.6 Hz, C(9)H); dC (125 MHz, DMSO-d6)
25.1, 25.6, 30.0, 32.4, 36.6, 46.9, 111.8, 111.9, 117.3, 117.7, 121.5,
122.9, 128.1, 129.8, 131.0, 133.0, 133.4, 140.8, 141.2, 141.6,
146.2, 166.1; m/z (ESI+) 414 ([M+H]+, 100%); HRMS (ESI+) C24H23N5
NaS ([M+Na]+) requires 436.1566; found 436.1555.
4.3.49. 20-(((5-Benzyl-5H-[1,2,4]triazino[5,6-b]indol-3-
yl)thio)methyl)benzonitrile (59)
Following General procedure 2, to 3-((20-cyanobenzyl)thio)-5H-
[1,2,4]triazino[5,6-b]indole 7 (50 mg, 0.15 mmol) in THF at 0 C,
was added NaH (60% dispersion in mineral oil, 10 mg, 0.24 mmol)
followed by benzyl bromide (25 lL, 0.24 mmol) and the resulting
mixture stirred at rt for 16 h. The reaction mixture was quenched
with water (30 mL) and CH2Cl2 (30 mL) added. The organic layer
was separated and washed with brine (30 mL), dried (MgSO4), ﬁl-
tered and concentrated in vacuo to yield the title compound (59)
as a light yellow solid (49 mg, 80%); mp (Gallenkamp) 197–
200 C; mmax (solid) 2215, 1571, 1520, 1468, 1328; HPLC (Method
2) >98%, tR = 11.96 min; dH (500 MHz, DMSO-d6, 363 K) 4.77 (2H,
s, S-CH2), 5.68 (2H, s, N-CH2), 7.23–7.33 (5H, m, C(200)H, C(300)H,
C(400), C(500)H and C(600)H), 7.42–7.45 (1H, m, C(8)H), 7.47–7.51
(1H, m, C(40)H), 7.53–7.56 (1H, m, C(7)H), 7.69–7.74 (2H, m,
C(30)H and C(60)H), 7.75–7.81 (2H, m, C(6)H and C(50)H), 8.37
(1H, d, J = 7.9 Hz, C(9)H); dC (125 MHz, DMSO-d6) 32.4, 44.2,
111.7, 111.9, 117.5, 117.6, 119.3, 121.7, 123.2, 127.3, 127.7,
128.1, 128.8, 130.2, 133.1, 133.2, 135.8, 140.7, 141.2, 141.5,
146.2, 166.2; m/z (ESI+) 430 ([M+Na]+, 100%); HRMS (ESI+) C24H17
N5NaS ([M+H]+) requires 430.1097; found 430.1081.
4.3.50. 5-Benzyl-3-(20-ﬂuorobenzylthio)-5H-[1,2,4]triazino[5,6-
b]indole (60)
Following General procedure 2, to 3-((2-ﬂuorobenzyl)thio)-5H-
[1,2,4]triazino[5,6-b]indole 14 (50 mg, 0.16 mmol) in THF at 0 C,
was added NaH (60% dispersion in mineral oil, 10 mg, 0.24 mmol)
followed by benzyl bromide (25 lL, 0.24 mmol) and the resulting
mixture stirred at rt for 16 h. The reaction mixture was quenched
with water (30 mL) and CH2Cl2 (30 mL) added. The organic layer
was separated and washed with brine (30 mL), dried (MgSO4), ﬁl-
tered and concentrated in vacuo to yield the title compound (60)
as a light yellow solid (26 mg, 40%); mp (Gallenkamp) 139–
141 C; mmax (solid) 3064, 1572, 1491, 1467, 1351, 1333, 1175;
HPLC (Method 2) >98%, tR = 12.17 min; dH (500 MHz, DMSO-d6,
363 K) 4.62 (2H, s, S-CH2), 5.67 (2H, s, N-CH2), 7.02–7.05 (1H, m,
C(50)H), 7.18 (1H, app t, J = 7.6 Hz, C(40)H), 7.25–7.35 (6H, m,
C(8)H, C(200)H, C(300)H, C(500)H, C(600)H and C(60)H), 7.49 (1H, app t,
J = 6.9 Hz, C(7)H), 7.56–7.59 (1H, m, C(40)H), 7.68–7.76 (2H, m,
C(6)H and C(30)H), 8.37 (1H, d, J = 7.9 Hz, C(9)H); dC (125 MHz,
DMSO-d6) 27.5, 44.2, 111.6, 115.3 (d, J = 21 Hz), 117.6, 121.7,
123.1, 124.4 (d, J = 2.9 Hz), 124.7, 127.3, 127.8, 128.8, 129.4 (d,
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141.0, 146.2, 160.5 (d, J = 246 Hz), 166.7; dF (470 MHz, DMSO-d6)
116.9; m/z (ESI+) 423 ([M+Na]+, 100%); HRMS (ESI+) C23H17FN4
NaS ([M+Na]+) requires 423.1050; found 423.1042.4.3.51. 20-(((5-(200-Nitrobenzyl)-5H-[1,2,4]triazino[5,6-b]indol-3-
yl)thio)methyl)benzonitrile (61)
Following General procedure 2, to 20(((5H-[1,2,4]triazino[5,6-
b]indol-3-yl)thio)methyl)benzonitrile 7 (60 mg, 0.19 mmol) in
THF (5 mL) was added NaH (60% dispersion in mineral oil,
11 mg, 0.28 mmol) followed by 2-nitro benzyl bromide (40 mg,
0.21 mmol) at 0 C and the resulting mixture stirred for 16 h at
rt. The reaction mixture was quenched with water until a
precipitate formed. The precipitate was ﬁltered and washed with
methanol to give the title compound (61) as an off white solid
(79 mg, 96%); mp (Gallenkamp) 225–226 C (dec); mmax (solid)
3061, 2804, 2226, 1580, 1340, 1175; HPLC (Method 2) >96%,
tR = 11.72 min; dH (500 MHz, pyr-d5, 363 K) 4.65 (2H, s, S-CH2),
6.02 (2H, s, N-CH2), 6.71 (1H, d, J = 7.1 Hz, C(600)H), 7.42–7.72
(7H, m, 7 Ar-H), 7.81–7.89 (2H, m, C(300 and C(6)H), 8.31 (1H,
d, J = 7.8 Hz, C(30)H), 8.40 (1H, d, J = 7.6 Hz, C(9)H); dC (125 MHz,
pyr-d5) 35.0, 45.2, 112.9, 115.0, 119.3, 119.9, 120.7, 124.0,
126.7, 129.3, 129.8, 130.4, 132.2, 133.0, 134.8, 134.8, 135.4,
141.1, 142.7, 143.7, 143.9, 148.9, 155.1, 169.2; m/z (ESI+) 452
([M+H]+, 10%), m/z (ESI) 316 ([M(200NO2Bn)H], 100%); HRMS
(ESI+) C24H16N6NaO2S ([MH]) requires 475.0948; found
475.954.4.3.52. 20-(((5-(Phenylsulfonyl)-5H-[1,2,4]triazino[5,6-b]indol-
3-yl)thio)methyl)benzonitrile (62)
Following General procedure 2, 20(((5H-[1,2,4]triazino[5,6-
b]indol-3-yl)thio)methyl)benzonitrile 7 (100 mg, 0.32 mmol) was
added to DMF (5 mL), cooled to 0 C followed by the addition of
NaH (60% dispersion in mineral oil, 13.8 mg, 0.35 mmol) and stir-
red at 0 C for 10 min. Phenyl sulfonyl chloride (40 lL, 0.32 mmol)
was added, stirred for 16 h and quenched with water. The resulting
precipitate was ﬁltered and dried to yield the title compound (62)
as a white solid (121 mg, 84%); mp (EZ Melt) 176–177 C; C23H15
N5NaO2S2 requires C, 60.38; H, 3.30; N, 15.31; found C, 60.26; H,
3.21; N, 15.16; mmax (solid) 2220, 1568, 1448, 1354, 1174; dH
(500 MHz, DMSO-d6, 363 K) 4.81 (2H, s, S-CH2), 7.52 (1H, app t,
J = 7.9 Hz, C(50)H), 7.63 (1H, app t, J = 7.6 Hz, C(8)H), 7.63 (2H,
app td, J = 8.8, 1.0 Hz, C(300)H and C(500)H), 7.69 (1H, app td,
J = 7.9, 1.6 Hz, C(40)H), 7.78 (1H, tt, J = 8.8, 1.0 Hz, C(400)H), 7.85
(1H, td, J = 7.6, 1.3 Hz, C(7)H), 7.89 (1H, d, J = 7.9 Hz, C(30)H), 7.91
(1H, dd, J = 7.9, 1.0 Hz, C(60)H), 8.10 (2H, dd, J = 8.8, 1.0 Hz, C(200)H
and C(600)H), 8.33 (1H, d, J = 7.6 Hz, C(6)H), 8.37 (1H, d, J = 7.6 Hz,
C(9)H); dC (125 MHz, DMSO-d6) 32.8, 112.0, 114.5, 117.5, 119.3,
121.8, 125.8, 127.4, 128.4, 130.0, 130.2, 132.2, 133.3, 133.4,
135.6, 136.8, 137.9, 140.7, 141.9, 147.1, 167.2; m/z (ESI+) 480
([M+Na]+, 100%); HRMS (ESI+) C23H15N5NaO2S2 ([M+Na]+) requires
480.0559; found 480.0549.4.3.53. 20-(((5-Tosyl-5H-[1,2,4]triazino[5,6-b]indol-3-
yl)thio)methyl)benzonitrile (63)
Following General procedure 2, 20(((5H-[1,2,4]triazino[5,6-
b]indol-3-yl)thio)methyl)benzonitrile 7 (60 mg, 0.19 mmol) was
added to THF (5 mL), cooled to 0 C followed by the addition of
NaH (60% dispersion in mineral oil, 11.0 mg, 0.28 mmol) and stir-
red at 0 C for 10 min. p-toluene sulfonyl chloride (40 mg,
0.21 mmol) was added, stirred for 16 h and quenched with water
(50 mL) and extracted with EtOAc (50 mL). The organic layer was
separated, washed with brine (30 mL), dried (MgSO4), ﬁltered and
concentrated in vacuo. The resulting solid was washed withmethanol to yield the title compound (63) as a white crystalline
solid (82 mg, 92%); mp (Gallenkamp) 220–222 C; mmax (solid)
2230, 1595, 1449, 1370, 1177; HPLC (Method 2) >99%, tR = 12.37 -
min; dH (500 MHz, DMSO-d6, 363 K) 2.28 (3H, s, C(40)CH3), 4.83
(2H, s, S-CH2), 7.37 (2H, d, J = 8.3 Hz, C(300)H and C(500)H), 7.49
(1H, app t, J = 7.8 Hz, C(40)H), 7.59 (1H, t, J = 7.8 Hz, C(8)H), 7.66
(1H, app t, J = 7.8 Hz, C(50)H), 7.82 (1H, app t, J = 7.8 Hz, C(7)H),
7.87–7.92 (2H, m, C(30)H and C(60)H), 8.01 (2H, d, J = 8.3 Hz,
C(200)H and C(600)H), 8.31–8.37 (2H, m, C(6)H and C(9)H); dC
(125 MHz, DMSO-d6) 21.2, 32.7, 112.0, 114.5, 117.5, 119.2,
121.8, 125.8, 127.4, 128.4, 130.2, 130.4, 132.2, 133.3, 133.4,
133.8, 137.9, 140.7, 141.8, 146.7, 147.0, 167.2; m/z (ESI+) 494
([M+Na]+, 45%), m/z (ESI) 316 ([M(2CNBn)], 100%); HRMS
(ESI+) C24H17N5NaO2S2 ([M+Na]+) requires 494.0716; found
494.0738.4.3.54. 20-(((200-Nitrophenylsulfonyl-5H-[1,2,4]triazino[5,6-
b]indol-3-yl)thio)methyl)benzonitrile (64)
Following General procedure 2, to 20(((5H-[1,2,4]triazino[5,6-
b]indol-3-yl)thio)methyl)benzonitrile 7 (60 mg, 0.19 mmol) in
THF (5 mL) was added NaH (60% dispersion in mineral oil,
11.0 mg, 0.28 mmol) at 0 C and stirred for 10 min. 2-Nitrophenyl
sulfonyl chloride (47 mg, 0.21 mmol) was added and the resulting
mixture stirred at rt for 16 h. The reaction mixture was quenched
dropwise with water (50 mL). The resulting precipitate was ﬁl-
tered and washed with methanol to yield the title compound
(64) as an off white solid (79 mg, 83%); mp (Gallenkamp) 217–
218 C; mmax (solid) 2921, 2853, 2228, 1546, 1373, 1184; HPLC
(Method 2) >97%, tR = 12.07 min; dH (500 MHz, DMSO-d6, 363 K)
4.70 (2H, s, S-CH2), 7.50 (1H, app t, J = 7.6 Hz, C(40)H), 7.63 (1H,
app t, J = 7.6 Hz, C(50)H), 7.67 (1H, app t, J = 7.6 Hz, C(400)H), 7.76
(1H, d, J = 7.6 Hz, C(60)H), 7.84–7.91 (2H, m, C(30)H and C(500)H),
7.97 (1H, app t, J = 7.6 Hz, C(8)H), 8.06 (1H, app t, J = 7.6 Hz,
C(7)H), 8.09 (1H, d, J = 8.5 Hz, C(600)H), 8.18 (1H, dd, J = 7.6,
1.3 Hz, C(6)H), 8.42 (1H, d, J = 7.6 Hz, C(300)H), 8.49 (1H, dd,
J = 7.6, 1.3 Hz, C(9)H); dC (125 MHz, DMSO-d6) 32.8, 112.0,
115.0, 117.4, 119.0, 121.8, 125.9, 126.0, 128.5, 129.4, 130.4,
132.3, 132.6, 133.2, 133.4, 133.5, 137.4, 138.6, 140.4, 141.9,
147.0, 147.1, 167.0; m/z (ESI) 501 ([MH], 20%), 316
([M(200-NO2PhSO2)H], 100%); HRMS (ESI+) C23H14N6NaO4S2
([M+Na]+) requires 525.0410; found 525.0425.4.3.55. Benzyl-3-((20-cyanobenzyl)thio)-5H-[1,2,4]triazino[5,6-
b]indole-5-carboxylate (65)
Following General procedure 2, to 20(((5H-[1,2,4]triazino[5,6-
b]indol-3-yl)thio)methyl)benzonitrile 7 (60 mg, 0.19 mmol) in
THF (5 mL) was added NaH (60% dispersion in mineral oil,
11.0 mg, 0.28 mmol) followed by benzyl chloroformate (23.4 lL
mg, 0.21 mmol) at 0 C and the resulting mixture stirred for 16 h
at rt. The reaction mixture was quenched with water and the
resulting precipitate was ﬁltered and washed with methanol to
yield the title compound (65) an off white solid (82 mg, 96%);
mp (Gallenkamp) 97–99 C; mmax (solid) 3426, 3063, 2232, 1739,
1582, 1392, 1195; dH (500 MHz, DMSO-d6, 363 K) 4.54 (2H, s,
S-CH2), 5.61 (2H, s, O-CH2), 7.26 (1H, t, J = 7.6 Hz, C(400)H), 7.35
(2H, app t, J = 7.6 Hz, C(300)H and C(500)H), 7.49 (1H, app t,
J = 7.6 Hz, C(40)H), 7.60–7.64 (4H, m, C(200)H and C(600)H, C(8)H
and C(50)H), 7.73 (1H, d, J = 7.6 Hz, C(60)H), 7.82 (1H, app t,
J = 7.6 Hz, C(7)H), 7.89 (1H, d, J = 7.6 Hz, C(30)H), 8.37 (1H, d,
J = 7.6 Hz, C(6)H), 8.39 (1H, d, J = 8.2 Hz, C(9)H); dC (125 MHz,
DMSO-d6) 32.4, 69.3, 111.9, 116.1, 117.4, 119.3, 121.3, 125.4,
128.4, 128.4, 128.4, 128.5, 130.6, 131.9, 133.1, 133.4, 134.7,
138.7, 140.8, 142.2, 147.0, 149.9, 167.3; m/z (ESI+) 474 ([M+Na]+,
20%), m/z (ESI) 316 ([M(PhCH2CO2)H], 100%); HRMS (ESI+)
C25H17N5NaO2S ([M+Na]+) requires 474.0995; found 474.0993.
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yl)thio)methyl)benzonitrile (66)
Following General procedure 2, to 20(((5H-[1,2,4]triazino[5,6-
b]indol-3-yl)thio)methyl)benzonitrile 7 (100 mg, 0.32 mmol) in
DMF (5 mL) was added NaH (60% dispersion in mineral oil,
13.8 mg, 0.35 mmol) followed by acetyl chloride (33.8 lL,
0.47 mmol) at 0 C and the resulting mixture stirred for 16 h. The
reaction mixture was quenched with water until a precipitate
formed. The precipitate was ﬁltered and dried to give the title com-
pound (66) as a pale yellow solid (89 mg, 77%); mp (Gallenkamp)
207–209 C; mmax (solid) 2227, 1721, 1377, 1177; HPLC (Method
2) >99%, tR = 11.53 min; dH (500 MHz, DMSO-d6, 363 K) 2.94 (3H,
s, CH3), 4.82 (2H, s, S-CH2), 7.51 (1H, app t, J = 7.6 Hz, C(50)H),
7.63 (1H, app t, J = 7.8 Hz, C(8)H), 7.70 (1H, app t, J = 7.6, Hz,
C(40)H), 7.81 (1H, app t, J = 7.8 Hz, C(7)H), 7.83 (1H, d, J = 7.6 Hz,
C(30)H), 7.90 (1H, d, J = 7.6 Hz, C(60)H), 8.38 (1H, d, J = 7.8 Hz,
C(6)H), 8.58 (1H, d, J = 7.8 Hz, C(9)H); dC (125 MHz, DMSO-d6)
27.4, 32.8, 112.0, 117.2, 117.4, 119.3, 121.2, 125.7, 128.4, 130.2,
132.1, 133.2, 133.5, 139.3, 140.5, 142.5, 147.3, 166.6, 170.3; m/z
(ESI+) 382 ([M+Na]+, 100%); HRMS (ESI+) C19H13N5NaOS
([M+Na]+) requires 382.0733; found 382.0724.
4.3.57. 20-(((5-(Cyclopropanecarbonyl)-5H-[1,2,4]triazino[5,6-
b]indole-3-yl)thio)methyl)benzonitrile (67)
Following General procedure 2, 20(((5H-[1,2,4]triazino[5,6-
b]indol-3-yl)thio)methyl)benzonitrile 7 (100 mg, 0.32 mmol) was
added to DMF (5 mL), cooled to 0 C followed by the addition of
NaH (60% dispersion in mineral oil, 13.8 mg, 0.35 mmol) and stir-
red at 0 C for 10 min. Cyclopropane carbonyl chloride (29 lL,
0.32 mmol) was added, stirred for 16 h at rt and quenched with
water. The resulting precipitate was ﬁltered and washed with
methanol to yield the title compound (67) as a white solid
(83 mg, 76%); mp (Gallenkamp) 183–184 C; mmax (solid) 3045,
2924, 2224, 1702; HPLC (Method 2) >99%, tR = 11.89 min; dH
(500 MHz, DMSO-d6, 363 K) 1.16–1.28 (4H, m, C(200)H2 and
C(300)H2), 3.50–3.56 (1H, m, C(100)H), 4.78 (2H, s, S-CH2), 7.5 (1H,
t, J = 7.9 Hz, C(8)H), 7.58 (1H, app t, J = 7.7 Hz, C(50)H), 7.69 (1H,
app td, J = 7.7, 1.2 Hz, C(40)H), 7.74 (1H, app t, J = 7.9 Hz, C(7)H),
7.80 (1H, d, J = 7.9 Hz, C(6)H), 7.89 (1H, dd, J = 7.7, 1.2 Hz, C(30)H),
8.33 (1H, d, J = 7.7 Hz, C(60)H), 8.46 (1H, d, J = 7.9 Hz, C(9)H); dC
(125 MHz, DMSO-d6) 11.6, 16.1, 32.8, 111.8, 117.1, 117.4, 119.1,
121.1, 125.6, 128.4, 130.0, 130.5, 131.9, 133.2, 133.5, 139.3,
142.5, 147.4, 166.4, 174.0; m/z (ESI+) 386 ([M+H]+, 100%); HRMS
(ESI+) C21H16N5OS ([M+H]+) requires 386.1073; found 386.1073.
4.3.58. 20-(((5-(Cyclopentanecarbonyl)-5H-[1,2,4]triazino[5,6-
b]indol-3-yl)thio)methyl)benzonitrile (68)
Following General procedure 2, to 20(((5H-[1,2,4]triazino[5,6-
b]indol-3-yl)thio)methyl)benzonitrile 7 (100 mg, 0.32 mmol) in
DMF (5 mL) was added NaH (60% dispersion in mineral oil,
13.8 mg, 0.35 mmol) followed by cyclopentane carbonyl chloride
(58 lL, 0.47 mmol) at 0 C and the resulting mixture stirred for
16 h at rt. The reaction mixture was quenched with water until a
precipitate formed. The precipitate was ﬁltered and dried to give
the title compound (68) as a pale yellow solid (56 mg, 42%); mp
(Gallenkamp) 173–174 C; mmax (solid) 2871, 2229, 1720, 1577,
1380; HPLC (Method 2) >99%, tR = 12.32 min; dH (500 MHz,
DMSO-d6, 363 K) 1.56–1.64 (2H, m, C(300)H and C(400)H), 1.66–
1.74 (2H, m, C(300)H and C400)H), 1.87–2.03 (4H, m, C(200)H and
C(500)H), 4.35–4.42 (1H, m, C(100)H), 4.81 (2H, s, S-CH2), 7.52 (1H,
app t, J = 7.6 Hz, C(8)H), 7.62 (1H, app t, J = 7.6 Hz, C(50)H), 7.71
(1H, app td, J = 7.6, 1.1 Hz, C(40)H), 7.79 (1H, app t, J = 7.6 Hz,
C(7)H), 7.80 (1H, d, J = 7.6 Hz, C(30)H), 7.92 (1H, d, J = 7.6 Hz,
C(60)H), 8.38 (1H, d, J = 7.6 Hz, C(6)H), 8.58 (1H, d, J = 7.6 Hz,
C(9)H); dC (125 MHz, DMSO-d6) 25.6, 29.5, 32.7, 45.9, 111.9,
117.4, 117.5, 119.5, 121.1, 125.7, 128.4, 130.4, 132.0, 133.2,133.6, 139.6, 140.2, 142.5, 147.0, 166.6, 176.3; m/z (ESI+) 436
([M+Na]+, 100%); HRMS (ESI+) C23H19N5NaOS ([M+Na]+) requires
436.1203; found 436.1198.
4.3.59. 20-(((5-(Cyclohexanecarbonyl)-5H-[1,2,4]triazino[5,6-
b]indol-3-yl)thio)methyl)benzonitrile (69)
Following General procedure 2, to 20(((5H-[1,2,4]triazino[5,6-
b]indol-3-yl)thio)methyl)benzonitrile 7 (100 mg, 0.32 mmol) in
DMF (5 mL) was added NaH (60% dispersion in mineral oil,
13.8 mg, 0.35 mmol) followed by cyclohexane carbonyl chloride
(63 lL, 0.47 mmol) at 0 C and the resulting mixture stirred for
16 h at rt. The reaction mixture was quenched with water until a
precipitate formed. The precipitate was ﬁltered and dried to give
the title compound (69) as a pale yellow solid (98 mg, 71%); mp
(Gallenkamp) 194–197 C; mmax (solid) 2932, 2854, 2226, 1720,
1453, 1379; HPLC (Method 2) >95%, tR = 12.67 min; dH (500 MHz,
DMSO-d6, 363 K) 1.18–1.38 (4H, m, C(300)H2 and C(500)H2), 1.45–
1.55 (2H, m, C(400)H2), 1.75–2.07 (4H, m, C(200)H2 and C(600)H2),
4.04–4.12 (1H, m, C(100)H), 4.84 (2H, s, S-CH2), 7.53 (1H, app td,
J = 7.6, 1.1 Hz, C(8)H), 7.60–7.65 (1H, m, C(40)H or C(60)H), 7.71
(1H, app td, J = 7.6, 1.1 Hz, C(7)H), 7.77–7.85 (2H, m, C(30)H and
C(40)H or C(60)H), 7.89–7.93 (1H, m, C(50)H), 8.38 (1H, d,
J = 6.9 Hz, C(6)H), 8.59 (1H, d, J = 8.5 Hz, C(9)H); dC (125 MHz,
DMSO-d6) 25.1, 25.3, 28.5, 32.8, 44.7, 112.0, 112.8, 117.4, 117.5,
119.6, 121.1, 125.7, 128.5, 130.4, 132.1, 133.6, 139.6, 140.3,
142.6, 147.0, 166.5, 176.2; m/z (ESI+) 450 ([M+Na]+, 100%); HRMS
(ESI+) C24H21N5NaOS ([M+Na]+) requires 450.1364; found
450.1362.
4.3.60. Methyl 400-(3-((20-cyanobenzyl)thio)-5H-
[1,2,4]triazino[5,6-b]indol-5-yl)-400-oxobutanoate (70)
Following General procedure 2, to 20(((5H-[1,2,4]triazino[5,6-
b]indol-3-yl)thio)methyl)benzonitrile 7 (150 mg, 0.47 mmol) in
DMF (5 mL) was added NaH (60% dispersion in mineral oil,
20.8 mg, 0.52 mmol) followed by methyl-5-chloro-5-oxopentoate
(87 lL, 0.71 mmol) at 0 C and the resulting mixture stirred at rt
for 16 h. The reaction mixture was quenched with water until a
precipitate formed. The precipitate was ﬁltered and dried to give
the title compound (70) as a pale yellow solid (165 mg, 81%); mp
(Gallenkamp) 144–145 C; mmax (solid) 2953, 2228, 1739, 1713,
1379, 1188; HPLC (Method 2) >99%, tR = 11.76 min; dH (500 MHz,
DMSO-d6, 363 K) 2.80 (2H, t, J = 6.3 Hz, N–C(O)–CH2), 3.62 (3H, s,
CH3), 3.69 (2H, t, J = 6.3 Hz, CH2–C(O)–O), 4.82 (2H, s, S-CH2),
7.51 (1H, app t, J = 7.6 Hz, C(8)H), 7.62 (1H, app t, J = 7.6 Hz,
C(50)H), 7.70 (1H, t, J = 7.6 Hz, C(40)H), 7.80 (1H, app t, J = 7.6 Hz,
C(7)H), 7.83 (1H, d, J = 7.6 Hz, C(30)H), 7.90 (1H, d, J = 7.6 Hz,
C(60)H), 8.38 (1H, d, J = 7.6 Hz, C(6)H), 8.56 (1H, d, J = 7.6 Hz,
C(9)H); dC (125 MHz, DMSO-d6) 27.9, 32.9, 34.2, 51.5, 111.9,
117.2, 117.4, 119.4, 121.2, 125.8, 128.4, 130.2, 132.1, 133.2,
133.5, 139.2, 140.5, 142.5, 147.3, 166.5, 172.3, 172.4; m/z (ESI+)
454 ([M+Na]+, 100%); HRMS (ESI+) C22H17N5NaO3S ([M+Na]+)
requires 454.0944; found 454.0924.
4.3.61. Methyl 500-(3-((20-cyanobenzyl)thio)-5H-
[1,2,4]triazino[5,6-b]indol-5-yl)-500-oxopentanoate (71)
Following General procedure 2, to 20(((5H-[1,2,4]triazino[5,6-
b]indol-3-yl)thio)methyl)benzonitrile 7 (150 mg, 0.47 mmol) in
DMF (5 mL) was added NaH (60% dispersion in mineral oil,
20.8 mg, 0.52 mmol) followed by methyl-5-chloro-5-oxopentoate
(98 lL, 0.71 mmol) at 0 C and the resulting mixture stirred at rt
for 16 h. The reaction mixture was quenched with water until a
precipitate formed. The precipitate was ﬁltered and dried to give
the title compound (71) as a pale yellow solid (170 mg, 81%); mp
(Gallenkamp) 166–167 C; mmax (solid) 2954, 2231, 1730, 1716,
1381; HPLC (Method 2)>99%, tR = 11.53 min; dH (500 MHz,
DMSO-d6, 363 K) 1.96–2.04 (2H, m, –CH2–) 2.44 (2H, t, J = 7.4 Hz,
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O-CH3), 4.78 (2H, s, S-CH2), 7.51 (1H, app t, J = 7.7 Hz, C(8)H),
7.60 (1H, t, J = 7.6 Hz, C(50)H), 7.69 (1H, app td, J = 7.7, 1.3 Hz,
C(40)H), 7.79 (1H, app td, J = 7.6, 1.3 Hz, C(7)H), 7.81 (1H, d,
J = 7.6 Hz, C(30)H), 7.91 (1H, d, J = 7.6 Hz, C(60)H), 8.33 (1H, d,
J = 7.6 Hz, C(6)H), 8.54 (1H, d, J = 7.8 Hz, C(9)H); dC (125 MHz,
DMSO-d6) 19.0, 32.3, 32.8, 38.9, 51.3, 112.0, 117.3, 117.4, 119.3,
121.1, 125.7, 128.5, 130.3, 132.1, 133.3, 133.6, 139.2, 140.4,
142.4, 147.1, 166.6, 172.9, 173.0; m/z (ESI+) 468 ([M+Na]+, 100%);
HRMS (ESI+) C22H17N5NaO3S ([M+Na]+) requires 468.1101; found
468.1107.
4.3.62. 20-(((5-(Benzoyl-5H-[1,2,4]triazino[5,6-b]indol-3-
yl)thio)methyl)benzonitrile (72)
Following General procedure 2, to 20(((5H-[1,2,4]triazino[5,6-
b]indol-3-yl)thio)methyl)benzonitrile 7 (100 mg, 0.32 mmol) in
DMF (5 mL) was added NaH (60% dispersion in mineral oil,
13.8 mg, 0.52 mmol) followed by benzoyl chloride (55 lL,
0.47 mmol) at 0 C and the resulting mixture stirred for 16 h. The
reaction mixture was quenched with water until a precipitate
formed. The precipitate was ﬁltered and dried to give the title com-
pound (72) as a pale yellow solid (97 mg, 72%); mp (Gallenkamp)
201–202 C; mmax (solid) 3056, 2228, 1699, 1600, 1290; C24H15N5
OS requires C, 68.39; H, 3.59; N, 16.62; found C, 68.19; H, 3.45;
N, 16.62; dH (500 MHz, DMSO-d6, 363 K) 4.06 (2H, s, S-CH2), 7.34
(1H, d, J = 7.9 Hz, C(60)H), 7.47 (1H, app t, J = 7.6 Hz, C(8)H), 7.52
(2H, app t, J = 7.3 Hz, C(300)H and C(500)H), 7.60 (1H, app t,
J = 7.9 Hz, C(50)H), 7.63 (1H, app t, J = 7.9 Hz, C(40)H), 7.66 (1H,
app t, J = 7.6 Hz, C(7)H), 7.82–7.86 (2H, m, C(30)H and C(400)H),
7.94 (2H, d, J = 7.3 Hz, C(200)H and C(600)H), 8.30 (1H, d, J = 7.6 Hz,
C(6)H), 8.44 (1H, d, J = 7.6 Hz, C(9)H); dC (125 MHz, DMSO-d6)
31.8, 111.7, 116.2, 117.2, 119.7, 121.3, 125.6, 128.3, 128.4, 130.0,
130.3, 131.6, 133.2, 133.2, 133.3, 133.9, 139.4, 140.2, 142.1,
147.2, 166.4, 167.8; m/z (ESI+) 444 ([M+Na]+, 100%); HRMS (ESI+)
C24H15N5NaOS ([M+Na]+) requires 444.0890; found 444.0885.
4.3.63. 20-(((5-(400-Fluorobenzoyl)-5H-[1,2,4]triazino[5,6-
b]indol-3-yl)thio)methyl)benzonitrile (73)
Following General procedure 2, to 20(((5H-[1,2,4]triazino[5,6-
b]indol-3-yl)thio)methyl)benzonitrile 7 (100 mg, 0.32 mmol) in
DMF (5 mL) was added NaH (60% dispersion in mineral oil,
13.8 mg, 0.35 mmol) followed by 4-ﬂuoro benzoyl bromide
(56 lL, 0.47 mmol) at 0 C and the resulting mixture stirred for
16 h. The reaction mixture was quenched with water until a pre-
cipitate formed. The precipitate was ﬁltered and dried to give the
title compound (73) as a pale yellow solid (95 mg, 67%); mp
(Gallenkamp) 202–204 C; mmax (solid) 2940, 2227, 1702, 1599,
1573, 1318; C24H14FN5OS requires C, 65.59; H, 3.21; N, 15.94;
found C, 65.31; H, 3.18; N, 15.98; dH (500 MHz, DMSO-d6, 363 K)
4.16 (2H, s, CH2), 7.34 (2H, app t, J = 8.8 Hz, C(300)H and C(500)H),
7.41 (1H, d, J = 7.6 Hz, C(30)H), 7.48 (1H, app td, J = 7.6, 1.3 Hz,
C(50)H), 7.62 (1H, td, J = 7.6, 1.3 Hz, C(8)H), 7.66 (1H, app t,
J = 7.6 Hz, C(40)H), 7.82–7.86 (2H, m, C(60)H and C(7)H), 7.98–8.06
(2H, m, C(200)H and C(600)H), 8.28 (1H, d, J = 7.8 Hz, C(6)H), 8.43
(1H, d, J = 7.6 Hz, C(9)H); dC (125MHz, DMSO-d6) 31.9, 111.7, 115.5
(d, J = 23 Hz), 116.3, 117.2, 119.7, 121.4, 125.6, 128.4, 130.2, 130.3
(d, J = 2.9 Hz), 131.7, 133.2, 133.2 (d, J = 9.5 Hz), 133.4, 139.5, 140.1,
142.2, 147.3, 165.1 (d, J = 253 Hz), 166.4, 166.7; dF (470 MHz,
DMSO-d6) 110.4; m/z (ESI+) 462 ([M+Na]+, 70%); HRMS (ESI+)
C24H14FN5NaOS ([M+Na]+) requires 462.0795; found 462.0794.
4.3.64. 20-(((5-(300-Triﬂuoromethyl)benzoyl)-5H-
[1,2,4]triazino[5,6-b]indol-3-yl)thio)methyl)benzonitrile (74)
Following General procedure 2, to 20(((5H-[1,2,4]triazino[5,6-
b]indol-3-yl)thio)methyl)benzonitrile 7 (100 mg, 0.32 mmol) in
THF (5 mL) was added NaH (60% dispersion in mineral oil,13.8 mg, 0.35 mmol) followed by 3-(triﬂuoromethyl)benzoyl chlo-
ride (71 lL, 0.47 mmol) at 0 C and the resulting mixture stirred for
16 h. The reaction mixture was quenched with water until a pre-
cipitate formed. The precipitate was ﬁltered, washed with metha-
nol and dried to give the title compound (74) as a pale yellow solid
(89 mg, 58%); mp (Gallenkamp) 155–156 C; mmax (solid) 2228,
1701, 1592, 1580, 1377, 1339; HPLC (Method 2) >96%, tR = 12.19 -
min; dH (500 MHz, DMSO-d6, 363 K) 4.74 (2H, s, S-CH2), 7.36 (1H, d,
J = 8.0 Hz, C(60)H), 7.46 7.68 (4H, m, C(7)H, C(8)H, C(40) and
C(500)H), 7.73–7.78 (2H, m, C(30)H and C(50)H), 7.95 (1H, s,
C(200)H), 8.18–8.23 (2H, m, C(400)H and C(600)H), 8.40 (1H, d,
J = 8.4 Hz, C(6)H), 8.43 (1H, d, J = 7.3 Hz, C(9)H); dC (125 MHz,
DMSO-d6) 31.8, 111.7, 116.6, 117.1, 119.8, 121.4, 123.7 (q,
J = 273 Hz), 125.9, 126.6 (q, J = 3.8 Hz), 128.4, 129.1 (q, J = 3.8 Hz),
129.1 (q, J = 32 Hz), 129.5, 130.2, 131.8, 133.2, 133.4, 133.6,
135.3, 139.4, 140.0, 142.5, 147.4, 166.2, 166.6; dF (470 MHz,
DMSO-d6) 61.2; m/z (ESI+) 512 ([M+Na]+, 100%); HRMS (ESI+)
C25H14F3N5NaOS ([M+Na]+) requires 512.0769; found 512.0759.
4.3.65. 20-(((5-(200-Triﬂuoromethyl-400-ﬂuorobenzoyl)-5H-
[1,2,4]triazino[5,6-b]indol-3-yl)thio)methyl)benzonitrile (75)
Following General procedure 2, to 20(((5H-[1,2,4]triazino[5,6-
b]indol-3-yl)thio)methyl)benzonitrile 7 (100 mg, 0.32 mmol) in
DMF (5 mL) was added NaH (60% dispersion in mineral oil,
13.8 mg, 0.35 mmol) followed by 2-triﬂuoromethyl-4-ﬂuoro ben-
zoyl bromide (72 lL, 0.47 mmol) at 0 C and the resulting mixture
stirred at rt for 16 h. The reaction mixture was quenched with
water until a precipitate formed. The precipitate was ﬁltered,
washed with methanol and dried to give the title compound (75)
as a pale yellow solid (67 mg, 42%); mp (EZ Melt) 193–194 C; mmax
(solid) 2230, 1716, 1384, 1292; HPLC (Method 2) >99%, tR = 12.18 -
min; dH (500 MHz, DMSO-d6, 363 K) 4.01 (2H, s, S-CH2), 7.50–7.54
(2H, m, C(8)H and C(30)H), 7.65 (1H, app td, J = 7.6, 1.3 Hz, C(50)H),
7.67–7.71 (1H, m, C(500)H), 7.73 (1H, app t, J = 7.6 Hz, C(40)H), 7.83
(1H, dd, J = 7.6, 1.3 Hz, C(300)H), 7.88 (1H, dd, J = 7.6, 1.6 Hz, C(60)H),
7.92 (1H, app td, J = 7.6, 1.3 Hz, C(7)H), 8.01–8.03 (1H, m, C(600)H),
8.46 (1H, d, J = 7.6 Hz, C(6)H), 8.62 (1H, d, J = 7.6 Hz, C(9)H); dC
(125 MHz, DMSO-d6) 31.8, 111.8, 114.5 (dq, J = 26, 4.8 Hz), 117.0,
117.0, 120.0 (d, J = 21 Hz), 120.2 (q, J = 276 Hz), 121.5, 123.7,
126.6, 128.4 (qd, J = 32, 7.6 Hz), 128.6, 130.2 (m), 130.2, 132.0 (d,
J = 8.6 Hz), 132.4, 133.2, 133.5, 138.9, 139.3, 142.5, 147.1, 161.7,
163.7, 165.7 (d, J = 238 Hz); dF (470 MHz, DMSO-d6) 102.4 (q,
J = 8.7 Hz), 53.8; m/z (ESI) 542 ([M+Cl], 40%); HRMS (ESI+)
C25H13F4N5NaOS ([M+Na]+) requires 530.0669; found 530.0678.
4.3.66. 20-(((5-(200-Nitrobenzoyl)-5H-[1,2,4]triazino[5,6-b]indol-
3-yl)thio)methyl)benzonitrile (76)
Following General procedure 2, 20(((5H-[1,2,4]triazino[5,6-
b]indol-3-yl)thio)methyl)benzonitrile 7 (100 mg, 0.32 mmol) was
added to DMF (5 mL), cooled to 0 C followed by the addition of
NaH (60% dispersion in mineral oil, 13.8 mg, 0.35 mmol) and stir-
red at 0 C for 10 min. 2-Nitrobenzoyl bromide (41.6 lL,
0.32 mmol) was added, stirred for 16 h and quenched with water.
The resulting precipitate was ﬁltered to yield the title compound
(76) as a white solid (119 mg, 81%); mp (EZ Melt) 210–213 C; mmax
(solid) 2261, 1711, 1524, 1453, 1383, 1346, 1292; dH (500 MHz,
DMSO-d6, 363 K) 3.97 (2H, s, S-CH2), 7.48–7.53 (2H, m, C(30)H
and C(50)H), 7.63 (1H, app td, J = 7.6, 1.3 Hz, C(40)H), 7.75 (1H,
app t, J = 7.6 Hz, C(7)H), 7.80 (1H, app td, J = 7.6, 1.3 Hz, C(400)H),
7.87 (1H, d, J = 7.6 Hz, C(60)H), 7.93 (1H, d, J = 7.6 Hz, C(600)H),
7.94 (1H, app td, J = 7.6, 1.3 Hz, C(8)H), 7.97 (1H, app td, J = 7.6,
1.3 Hz, C(500)H), 8.27 (1H, d, J = 7.6 Hz, C(300)H), 8.47 (1H, d,
J = 7.6 Hz, C(6)H), 8.73 (1H, d, J = 7.6 Hz, C(9)H); dC (125 MHz,
DMSO-d6) 31.9, 111.8, 117.2, 119.8, 121.6, 124.4, 126.6, 128.6,
129.0, 130.3, 131.6, 131.7, 132.5, 133.2, 133.5, 135.6, 138.8,
139.4, 142.3, 144.7, 146.7, 146.8, 164.7, 166.8; m/z (ESI+) 489
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489.0740; found 489.0733.
4.3.67. 20-(((5-(400-(Triﬂuoromethoxy)benzoyl)-5H-
[1,2,4]triazino[5,6-b]indol-3-yl)thio)methyl)benzonitrile (77)
Following General procedure 2, to 20(((5H-[1,2,4]triazino[5,6-
b]indol-3-yl)thio)methyl)benzonitrile 7 (100 mg, 0.32 mmol) in
DMF (5 mL) was added NaH (60% dispersion in mineral oil,
13.8 mg, 0.35 mmol) followed by 4-(triﬂuoromethoxy)benzoyl
chloride (74 lL, 0.47 mmol) at 0 C and the resulting mixture stir-
red for 16 h at rt. The reaction mixture was quenched with water
until a precipitate formed. The precipitate was ﬁltered and dried
to give the title compound (77) as a white solid (109 mg, 67%);
mp (Gallenkamp) 169–170 C; mmax (solid) 2926, 2224, 1701,
1458; HPLC (Method 2) >97%, tR = 12.07 min; dH (500 MHz,
DMSO-d6, 363 K) 4.08 (2H, s, S-CH2), 7.39 (1H, d, J = 7.6 Hz,
C(60)H), 7.45–7.53 (3H, m, C(300)H, C(500)H and C(8)H), 7.61 (1H,
app td, J = 7.7, 1.2 Hz, C(7)H), 7.68 (1H, app t, J = 7.4 Hz, C(40)H),
7.81–7.88 (2H, m, C(30)H and C(50)H), 8.08–8.14 (2H, m, C(200)H
and C(600)H), 8.37 (1H, d, J = 7.7 Hz, C(6)H), 8.43 (1H, d, J = 7.3 Hz,
C(9)H); dC (125 MHz, DMSO-d6) 32.5, 111.7, 116.5, 117.1, 119.7,
120.4, 120.7, 121.3, 125.8, 128.5, 129.5 (q, J = 258 Hz), 130.3,
131.7, 132.4, 133.1, 133.4, 139.4, 140.0, 142.2, 147.3, 151.4,
166.6, 170.3; dF (470 MHz, DMSO-d6) 56.8; m/z (ESI+) 528
([M+Na]+, 50%); HRMS (ESI+) C25H14F3N5NaO2S ([M+Na]+) requires
528.0718; found 528.0713.
4.3.68. 20-(((5-(400-Dimethylamino)benzoyl)-5H-
[1,2,4]triazino[5,6-b]indol-3-yl)thio)methyl)benzonitrile (78)
To a stirred suspension of 20(((5H-[1,2,4]triazino[5,6-b]indol-3-
yl)thio)methyl)benzonitrile 7 (100 mg, 0.32 mmol), DMAP (0.8 mg,
0.06 mmol) and Et3N (86 lL, 0.63 mmol) in CH2Cl2 (5 mL) at rt was
added 4-dimethylaminobenzoyl chloride (83 mg, 0.48 mmol). The
resulting mixture was stirred at rt for 16 h. CH2Cl2 (30 mL) was
added to the suspension and washed with H2O (30 mL). The
organic layer was washed with brine (30 mL), dried (MgSO4), ﬁl-
tered and concentrated in vacuo. The resulting solid was washed
with methanol and dried to yield the title compound (78) as a
white solid (81 mg, 55%); mp (Gallenkamp) 196–197 C; mmax
(solid) 2917, 2229, 1679, 1603, 1184; HPLC (Method 2) >95%,
tR = 12.15 min; dH (400 MHz, pyr-d5, 363 K) 2.84 (6H, s, N-CH3),
5.04 (2H, s, S-CH2), 6.74 (2H, d, J = 9.1 Hz, C(300)H and C(500)H),
7.28 (1H, app t, J = 7.6 Hz, C(8)H), 7.45 (1H, app t, J = 7.6 Hz,
C(7)H), 7.56 (1H, app t, J = 7.6 Hz, C(40)H), 7.59 (1H, d, J = 7.6 Hz,
C(30)H), 7.62–7.71 (2H, m, C(50)H and C(60)H), 8.08 (2H, d,
J = 9.1 Hz, C(200)H and C(600)H), 8.19 (1H, d, J = 7.6 Hz, C(6)H), 8.48
(1H, d, J = 7.6 Hz, C(9)H); dC (125 MHz, pyr-d5) 33.5, 39.7, 111.2,
113.2, 116.2, 118.1, 119.4, 120.2, 121.9, 125.1, 128.4, 131.1,
131.5, 133.2, 133.5, 134.0, 140.9, 141.7, 142.4, 147.6, 154.9,
166.8, 168.0; m/z (ESI) 463 ([MH], 50%); HRMS (ESI+) C26H20
N6NaOS ([M+Na]+) requires 487.1312; found 487.1310.
4.3.69. 20-(((5-(300,400-Dimethoxybenzoyl)-5H-[1,2,4]triazino[5,6-
b]indol-3-yl)thio)methyl)benzonitrile (79)
To a stirred suspension of 20(((5H-[1,2,4]triazino[5,6-b]indol-3-
yl)thio)methyl)benzonitrile 7 (100 mg, 0.32 mmol), DMAP (0.8 mg,
0.06 mmol) and Et3N (86 lL, 0.63 mmol) in CH2Cl2 (5 mL) at rt was
added 3,4-dimethoxybenzoyl chloride (95 mg, 0.48 mmol). The
resulting mixture was stirred at rt for 16 h. CH2Cl2 (30 mL) was
added to the suspension and washed with water (30 mL). The
organic layer was washed with brine (30 mL), dried (MgSO4), ﬁl-
tered and concentrated in vacuo. The resulting solid was washed
with methanol and dried to yield the title compound (79) as a
white solid (87 mg, 56%); mp (Gallenkamp) 234–235 C; mmax
(solid) 3115, 2932, 2229, 1697, 1514, 1378; HPLC (Method 2)
>99%, tR = 11.81 min; dH (500 MHz, DMSO-d6, 363 K) 3.73 (3H, s,O-CH3), 3.80 (3H, s, O-CH3), 4.25 (2H, s, S-CH2), 7.09 (1H, d,
J = 8.5 Hz, C(500)H), 7.35 (1H, d, J = 7.9 Hz, C(30)H), 7.46 (1H, app
td, J = 7.6, 1.3 Hz, C(50)H), 7.55 (1H, d, J = 1.9 Hz, C(200)H), 7.59
(1H, td, J = 7.6, 1.3 Hz, C(40)H), 7.63–7.67 (2H, m, C(8)H and
C(600)H), 7.80–7.85 (2H, m, C(7)H and C(6)0), 8.14 (1H, d,
J = 8.5 Hz, C(6)H), 8.43 (1H, d, J = 7.9 Hz, C(9)H); dC (125 MHz,
DMSO-d6) 32.1, 55.8, 55.9, 110.8, 111.7, 113.4, 115.9, 117.2,
119.5, 121.4, 125.1, 125.3, 125.5, 128.3, 130.2, 131.5, 133.2,
133.2, 139.7, 140.5, 142.2, 147.3, 148.4, 153.8, 166.3, 166.8; m/z
(ESI+) ([M+Na]+, 100%); HRMS (ESI+) C26H19N5NaO3S ([M+Na]+)
requires 504.1110; found 504.1107.
4.3.70. 20-(((5-(Furan-200-carbonyl)-5H-[1,2,4]triazino[5,6-
b]indol-3-yl)thio)methyl)benzonitrile (80)
Following General procedure 2, to 20(((5H-[1,2,4]triazino[5,6-
b]indol-3-yl)thio)methyl)benzonitrile 7 (100 mg, 0.32 mmol) in
DMF (5 mL) was added NaH (60% dispersion in mineral oil,
13.8 mg, 0.35 mmol) followed by furan-2-carbonyl chloride
(46 lL, 0.47 mmol) at 0 C and the resulting mixture stirred for
16 h. The reaction mixture was quenched with water until a pre-
cipitate formed. The precipitate was ﬁltered and dried to give the
title compound (80) as a pale yellow solid (103 mg, 78%); mp
(Gallenkamp) 177–178 C; mmax (solid) 2924, 2227, 1692, 1382,
1309; HPLC (Method 2) >97%, tR = 11.63 min; dH (500 MHz,
DMSO-d6, 363 K) 4.49 (2H, s S-CH2), 6.83 (1H, dd, J = 3.8, 1.8 Hz,
C(400)H), 7.46 (1H, app td, J = 7.6, 1.3 Hz, C(50)H), 7.53 (1H, d,
J = 7.6 Hz, C(60)H), 7.59 (1H, app t, J = 7.8 Hz, C(8)H), 7.60–7.64
(1H, m, C(40)H), 7.73–7.80 (2H, m, C(7)H and C(500)H), 7.84 (1H,
dd, J = 7.6, 1.0 Hz, C(30)H), 8.02 (1H, d, J = 8.3 Hz, C(6)H), 8.20 (1H,
dd, J = 3.8, 0.8 Hz, C(300)H), 8.38 (1H, d, J = 7.8 Hz, C(9)H); dC
(125 MHz, DMSO-d6) 33.3, 112.7, 114.0, 116.1, 118.2, 120.0,
122.3, 125.1, 126.2, 129.2, 131.1, 132.4, 134.1, 134.2, 139.9,
141.3, 142.7, 146.5, 147.8, 150.8, 156.4, 167.3; m/z (ESI+) 434
([M+Na]+, 100%); HRMS (ESI+) C22H13N5NaO2S ([MH]) requires
434.0682; found 434.0680.
4.3.71. 20-(((5-(Isoxazole-500-carbonyl)-5H-[1,2,4]triazino[5,6-
b]indol-3-yl)thio)methyl)benzonitrile (81)
Following General procedure 2, to 20(((5H-[1,2,4]triazino[5,6-
b]indol-3-yl) thio) methyl)benzonitrile 7 (100 mg, 0.32 mmol) in
DMF (5 mL) was added NaH (60% dispersion in mineral oil,
13.8 mg, 0.35 mmol) followed by isoxazole-5-carbonyl chloride
(62 lL, 0.47 mmol) at 0 C and the resulting mixture stirred for
16 h. The reaction mixture was quenched with water until a pre-
cipitate formed. The precipitate was ﬁltered and dried to give the
title compound (81) as a pale yellow solid (112 mg, 85%); mp
(Gallenkamp) 195–196 C; mmax (solid) 2923, 2227, 1709, 1299;
HPLC (Method 2) >95%, tR = 11.47 min; dH (500 MHz, DMSO-d6,
363 K) 4.44 (2H, s, CH2), 7.48 (1H, d, J = 1.9 Hz, C(500)H), 7.49 (1H,
app td, J = 7.6, 1.3 Hz, C(50)H), 7.60–7.67 (2H, m, C(8)H and
C(7)H), 7.69 (1H, app t, J = 7.6 Hz, C(40)H), 7.83–7.88 (2H, m,
C(30)H and C(60)H), 8.33 (1H, d, J = 7.6 Hz, C(6)H), 8.44 (1H, d,
J = 7.6 Hz, C(9)H), 8.91 (1H, d, J = 1.9 Hz, C(400)H); dC (125 MHz,
DMSO-d6) 32.4, 110.8, 111.9, 116.4, 117.3, 119.8, 121.6, 126.4,
128.5, 130.4, 132.1, 133.3, 133.5, 138.6, 140.2, 142.3, 147.3,
151.6, 155.6, 160.5, 166.6; m/z (ESI+) 413 ([M+Na]+, 100%); HRMS
(ESI+) C21H12N6NaO2S ([M+Na]+) requires 413.0815; found
340.0610 (corresponds to parent compound).
4.3.72. 20-(((5-(Morpholine-400-carbonyl)-5H-[1,2,4]triazino[5,6-
b]indol-3-yl)thio)methyl)benzonitrile (82)
Following General procedure 2, 20(((5H-[1,2,4]triazino[5,6-
b]indol-3-yl)thio)methyl)benzonitrile 7 (100 mg, 0.32 mmol) was
added to DMF (5 mL), cooled to 0 C followed by the addition of
NaH (60% dispersion in mineral oil, 13.8 mg, 0.34 mmol) and stir-
red at 0 C for 10 min. 1-Morpholine carbonyl chloride (47 lL,
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quenched slowly with dropwise addition of water. The resulting
precipitate was ﬁltered and dried to yield the title compound
(82) as a white solid (98 mg, 72%); mp (EZ Melt) 191–193 C; mmax
(solid) 2928, 2867, 2223, 1688, 1570, 1389; HPLC (Method 2) >99%,
tR = 10.86 min; dH (500 MHz, DMSO-d6, 363 K) 3.40–3.79 (8H, m,
8 CH), 4.78 (2H, s, S-CH2), 7.50 (1H, app td, J = 7.8, 1.3 Hz,
C(50)H), 7.57 (1H, app t, J = 7.6 Hz, C(8)H), 7.68 (1H, app td,
J = 7.8, 1.3 Hz, C(40)H), 7.76 (1H, d, J = 7.8 Hz, C(30)H), 7.79 (1H,
app t, J = 7.6 Hz, C(7)H), 7.83 (1H, d, J = 7.6 Hz, C(6)H), 7.89 (1H,
dd, J = 7.8, 1.3 Hz, C(60)H), 8.37 (1H, d, J = 7.6 Hz, C(9)H); dC
(125 MHz, DMSO-d6) 32.7, 44.7, 66.1, 112.0, 113.9, 117.5, 118.5,
121.6, 124.3, 128.3, 130.4, 131.5, 133.2, 133.3, 139.4, 140.9,
141.8, 145.7, 148.4, 166.3; m/z (ESI+) 453 ([M+Na]+, 100%); HRMS
(ESI+) C22H18N6NaO2S ([M+Na]+) requires 453.1104; found
453.1087.4.4. Pharmacology
4.4.1. 1hCB2R and hCB1R cAMP assay
The cAMP Hunter eXpress GPCR assay kit and cells used are
from DiscoveRx Corporation (DiscoveRx Corporation, Birmingham,
UK) and used according to the manufacturer’s protocol. The CB2R
agonist 4-[4-(1,1-dimethylheptyl)-2,6-dimethoxyphenyl]-6,6-
dimethylbicyclo[3.1.1]hept-2-ene-2-methanol (HU-308 from
Tocris Bioscience, UK) and the CB1R agonist N-(2-Chloroethyl)-
5Z,8Z,11Z,14Z-eicosatetraenamide (ACEA from Tocris Bioscience,
UK) were used as positive controls in the hCB2R and hCB1R assays,
respectively. Brieﬂy, hCB2R or hCB1R CHO-K1 cells were plated in
the provided medium (15,000 cells per well) in half-area 96-well
plates (Corning, UK) and placed overnight in an incubator 37 C
5% CO2. From this stage onwards, the assays for CB1R and CB2R
CHO-K1 cells were identical. Next day, the medium was aspirated
and replaced with a 1:3 solution of anti-cAMP antibody in provided
buffer. In the presence of 20 lM forskolin, freshly reconstituted
compounds or solvent alone (ﬁnal concentration 0.2% DMSO) were
added to the wells and incubated for 30 min at 37 C, 5% CO2. After
the incubation, a mixture of provided lysis solution and substrates
was added to the wells and incubated in the dark for one hour at
room temperature. The provided detection reagent EA was then
added to the wells and incubated in the dark for 3 h at room tem-
perature. The luminescence was then read using a standard lumi-
nometer (Perkin–Elmer, Seer Green, UK). The luminescence of the
wells incubated only with forskolin and solvent (control wells)
were normalised as 100% and the dose–response curves were
expressed as a percentage of the control wells. The EC50 values
shown are from pooling 3–4 independent experiments and were
identiﬁed using GraphPad prism non-linear regression curve ﬁt
(4 PL parameters).4.4.2. Radioligand binding assays: hCB1R and hCB2R
Radioligand binding assays were contracted to CEREP (Celle
l’Evescault, France) where membranes from CHO-cells expressing
either hCB1R or hCB2R were used to assess binding to the two can-
nabinoid receptors. Competition binding studies were performed
by incubating membranes expressing hCB1R or hCB2R with unla-
beled compounds and tritiated CP 55,940 (0.5 nM) or WIN-55212
(0.8 nM) respectively, for two hours at 37 C. For CB1R and CB2R,
non-speciﬁc binding was assessed using WIN-55212 at 10 and
5 lM, respectively. Two hours later, the binding of tritiated ligands
was assessed by scintillation counting. The competition binding
data for each compound are expressed as the percentage of the
remaining bound tritiated ligand after the compound’s incubation
with the membrane. Ki values (equilibrium dissociation constants
for each compound) were calculated from CEREP using theCheng–Prusoff equation and the Kd value (equilibrium dissociation
constant for each radioligand).
4.5. In vitro molecular properties
4.5.1. Solubility studies
The aqueous solubility assay was performed by Cyprotex using
a high throughput turbidimetric assay. Initially, a stock DMSO
solution was diluted in DMSO to produce a range of concentra-
tions. These were then added to phosphate buffered saline at pH
7.4 (ﬁnal test compound concentrations = 1 lM, 3 lM, 10 lM,
30 lM, 100 lM, ﬁnal DMSO concentration = 1%, 7 replicates per
concentration) and incubated for 2 h at 37 C. At the end of the
incubation period, the absorbance at 620 nM was read for each
concentration and each replicate. The assay provided a precipita-
tion range, where the mid-point was used as the estimated precip-
itation concentration and recorded in lM.
4.5.2. Microsomal stability studies
The microsomal stability assay was performed by Cyprotex plc.
The microsomes used were derived from mouse liver and were
incubated with the test compound at 37 C in the presence of
added co-factor, NADPH. The reaction was terminated by the addi-
tion of methanol containing an internal standard. Following centri-
fugation, the supernatant was analysed by LC–MS/MS. The
disappearance of test compound was monitored at 0, 5, 15 30,
45 min time points. Diazepam and diphenhydramine were used
as the positive controls. Compound stability in the absence of
added co-factor was measured at the 45 min time point.
4.5.3. Cellular permeability studies
Cell permeability studies were carried out by Cyprotex using
MDR1-transfected (MDR1-MDCK) cells derived from Madin Darby
canine kidney (MDCK) cells. The cells were plated on a Multiscreen
plate (Millipore, MA, USA) and formed a conﬂuent monolayer over
a period of 4 days before the experiment. On day 4, the test com-
pounds were applied to the apical side of the membrane and the
transport of the compound across the monolayer was monitored
over a 60 min time period. The efﬂux ratio of the desired com-
pound was measured by determining transport of the compound
from the basolateral area to the apical compartment.
4.6. Molecular modelling
Energy minimisations were performed for 51, 52 and 53 using
Maestro molecular modelling software (version 9.0 Schrodinger).
The calculations were performed ignoring solvent interactions,
and the force ﬁeld used was MM2. In each case an evaluation of
the model was performed by a Ramachandran plot. The selection
of most the plausible structural pose(s) was done by observation
of the energy minimization score results.Acknowledgments
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